The endocannabinoid system and autistic behavior in the Fmr1- KO mouse by Lenz, Frederike
Aus der Klinik und Poliklinik für Psychiatrie und Psychotherapie  
Universitätsklinikum Carl Gustav Carus der TU Dresden 
Direktor: Herr Prof. Dr. med. Dr. rer. nat. Michael Bauer 
 
 
 
 
 
 
 
The endocannabinoid system and autistic behavior  
in the Fmr1- KO mouse 
 
 
 
 
Dissertationsschrift 
zur Erlangung des akademischen Grades 
Doktor der Medizin 
Doctor medicinae (Dr. med.) 
vorgelegt 
der Medizinischen Fakultät Carl Gustav Carus 
der Technischen Universität Dresden 
 
von 
 
Frederike Elisabeth Lenz 
aus Hamburg 
 
Dresden, Dezember 2016 
 
 
 
 
 
 
 
 
 ii 
1. Gutachter:  
 
 
 
 
 
 
 
2. Gutachter:  
 
 
 
 
 
 
Tag der mündlichen Prüfung: 
 
 
 
 
 
 
 
gez.:                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
 
Acknowledgement. 
 
I would like to thank everyone who has made this work possible! 
 
First of all I would like to thank the group and laboratory around Dr. Susanna Pietro-
paolo and Dr. Wim Crusio from the “Institute de Neurosience Cognitive et Intégratives 
d’Aquitaine”, University of Bordeaux as well as the group and laboratory around Dr. 
Etienne Chatelaine and Dr. Giovanni Marsicano at the “Institute national de la santé et 
de la recherche médicale, laboratoire de physiopathology de la plasticité neuronale” at 
the Neurocentre Magendi in Bordeaux. All experimental procedures have been pro-
ceeded in these facilities under the mentioned supervision.  
 
Further, I would like to thank my friend and supervisor Dr. Lydia Günther from the “Klin-
ik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav 
Carus” of the Universtiy of Dresden who supervised and supported me during experi-
mentation, writing and presenting this work, as well as Prof. Christine Winter, from the 
“Charité Universitätsmedizin Berlin”, Department of Neurology for her official support 
and expert opinion. 
 
Finally, I would like to thank my very good friend Dipl.- Psych. Robert Czernicka for all 
his patience and ambition to help me with statistical, mental and interpersonal difficul-
ties during and after the development of this work! 
 
 
 
 
 
 
 
 
 
“ Confidence is what you have before you understand the problem” – Woody Allen 
	  
 iv 
Table of Contents 
1 Introduction ................................................................................................................ 1	  
1.1 Autism Spectrum Disorder ................................................................................ 1	  
1.2 Animal models for Autism Spectrum Disorder ................................................ 3	  
1.2.1 A mouse model for Fragile X Syndrome ........................................................ 4	  
1.2.2 Autistic behavior in the Fmr1- KO mouse ...................................................... 6	  
1.2.3 Biochemical mechanisms underlying the Fmr1- KO phenotype .................... 7	  
1.3 Role of the Endocannabinoid System in the development of autistic 
behavior in the Fmr1- KO mouse ............................................................................ 8	  
1.4 Aims of this work .............................................................................................. 12	  
2 Materials and Methods ............................................................................................ 12	  
2.1 Animals .............................................................................................................. 14	  
2.2 Pharmacological treatment ............................................................................. 15	  
2.3 Behavioral tests ................................................................................................ 15	  
2.3.1 Experiment 1: Tetrad experiment and social interaction task ...................... 15	  
2.3.2 Experiment 2: Social interaction task with pre- treatment of a CB1- 
antagonist ............................................................................................................. 18	  
2.3.3 Experiment 3: Context recognition task ....................................................... 19	  
2.4 Western blot ...................................................................................................... 20	  
2.4.1 Experiment 4: Western blot ......................................................................... 22	  
2.5 Statistical methods ........................................................................................... 24	  
3 Results ...................................................................................................................... 25	  
3.1 Behavioral tests ................................................................................................ 25	  
3.1.1 Experiment 1: Tetrad experiment and social interaction task ...................... 25	  
3.1.2 Experiment 2: Social interaction task with pre- treatment of a CB1- 
antagonist ............................................................................................................. 35	  
3.1.3 Experiment 3: Context recognition task ....................................................... 37	  
3.2 Experiment 4: Western blot ............................................................................. 39	  
3.2.1 Effect of THC treatment on kinase- phosphorylation in hippocampus ......... 39	  
3.2.2 Effect of THC treatment on kinase- phosphorylation in striatum ................. 41	  
3.2.3 Effect of THC treatment on kinase- phosphorylation in cortex .................... 42	  
3.2.4 Effect of THC treatment on kinase- phosphorylation in cerebellum ............ 44	  
4 Discussion ............................................................................................................... 45	  
 v 
4.1 Behavioral tests ................................................................................................ 45	  
4.1.1 Fmr1 KO mice display a desensitized endocannabinoid system ................ 45	  
4.1.2 THC possibly restores impairment in social interaction in Fmr1- KO mice .. 48	  
4.1.3 THC can reduce social interaction in wild- type mice 10 days after treatment
 .............................................................................................................................. 49	  
4.1.4 THC possibly restores impaired associative fear memory consolidation in 
Fmr1- KO mice ..................................................................................................... 50	  
4.2 Western blot reveals altered activity of CB1 downstream targets in Fmr1- 
KO mice ................................................................................................................... 52	  
4.3 Conclusion ........................................................................................................ 55	  
Abstract ....................................................................................................................... 56	  
Zusammenfassung ..................................................................................................... 59	  
Literature	  
Addendum	  
 
 vi 
List of tables 
 
Table 1: Pharmacological treatment of mice ................................................................ 15	  
Table 2: Number (N) of mice per genotype and treatment group, that took part in each 
of the three tasks of experiment 1, the tetrad experiment and the social interaction 
task (SIT) after 10 days and after 20 days ............................................................ 18	  
Table 3: Number (N) of WT- mice per pre-treatment and treatment group that took part 
in the repetition of social interaction task 10 days after treatment. Numbers of mice 
that were used for statistical analyzes are put in brackets in case of drop outs. ... 18	  
Table 4: Number (N) of mice per genotype and treatment group that took part in 
context recognition task. Number of mice that were used for statistical analyzes is 
put in brackets in case of drop outs. ...................................................................... 20	  
Table 5: Number (N) of mice per genotype and treatment group, which were used for 
western blotting of hippocampus. In brackets number of mice used for statistical 
analyzes after exclusion of statistical outliers. ....................................................... 20	  
Table 6: Number of mice per genotype and treatment group, which were used for 
western blotting of striatum. In brackets number of mice used for statistical 
analyzes after exclusion of statistical outliers. ....................................................... 21	  
Table 7: Number of mice per genotype and treatment group, which were used for 
western blotting of cortex. In brackets number of mice used for statistical analyzes 
after exclusion of statistical outliers. ...................................................................... 21	  
Table 8: Number of mice per genotype and treatment group, which were used for 
western blotting of cerebellum. In brackets number of mice used for statistical 
analyzes after exclusion of statistical outliers. (p)AKT detection in cerebellum is 
not presented due to experimentation errors. ....................................................... 21	  
Table 9: Procedure of western blotting ......................................................................... 22	  
 
  
 vii 
List of figures 
 
Figure 1: Endocannabinoid signaling, adapted from Kano et al., (2009). The figure 
shows endocannabinoid synthesis, release and action. mGluR= metabotropic 
glutamate receptor, PLC= phospholipase C, araG= arachidonate group, DAG= 
diacylglycerol, DGL= diacylglycerol lipase, NAPE PLD= phospholipid diesterase, 
AEA= Anandamide, 2AG= 2- Arachidonylglycerol). .............................................. 10	  
Figure 2: CB1 signaling (André and Gonthier 2010), modified. The figure shows G-
protein-mediated signaling pathways of CB1. Protein kinases that are in focus of 
this study are highlighted in bold. .......................................................................... 11	  
Figure 3: Synopsis of experiments in sequence and procedure. It shows Fmr1- KO 
(white) and WT (black) mice from the B6 background in order of experimentation. 
Animals of each experiment 1 to 4 were naive before testing. .............................. 13	  
Figure 4: Test procedure of the tetrad experiment ....................................................... 16	  
Figure 5: Test procedure of the social interaction tasks ............................................... 17	  
Figure 6: Test procedure of the context recognition task ............................................. 19	  
Figure 7: Exemplifies errors in western blot membrane (1., *) compared to an accurate 
one (2.) for detection of pERK in cortex. Errors of this kind result in deficient 
quantification of values for optical density and are therefore not evaluable. ......... 21	  
Figure 8: Exemplifies an outlier (* 27) of the western blot results, which was excluded 
from statistical analyzes. ....................................................................................... 21	  
Figure 9: Effect of THC compared to vehicle on wild- type (WT) n and knock- out (KO) 
☐ - mice on body temperature decrease. Significance is shown as “*“ for 
interaction effects and subsequent post- hoc test at p< 0.05, main effects are 
pictured with brackets. ........................................................................................... 25	  
Figure 10: Effect of WIN55,212 compared to vehicle on wild- type (WT) n and knock- 
out (KO) ☐ - mice on body temperature decrease. Significance for main effects 
are pictured with brackets. .................................................................................... 26	  
Figure 11: Effect of THC compared to vehicle on wild- type (WT) n and knock- out 
(KO) ☐ - mice on the distance moved in an open field. Significance is shown as “*“ 
for interaction effects and subsequent post- hoc test at p< 0.05, main effects are 
pictured with brackets. ........................................................................................... 27	  
Figure 12: Effect of WIN55,212 compared to vehicle on wild- type (WT) n and knock- 
out (KO) ☐ - mice on the distance moved in an open field. Significance is shown 
as “*“ for interaction effects and subsequent post- hoc test at p< 0.05, main effects 
are pictured with brackets. .................................................................................... 28	  
 viii 
Figure 13: Effect of THC compared to vehicle on wild- type (WT) n and knock- out 
(KO) ☐ - mice on the descent latency from a 1cm diameter bar. Significance is 
shown as “*“ for interaction effects and subsequent post- hoc test at p< 0.05, main 
effects are pictured with brackets. ......................................................................... 29	  
Figure 14: Effect of WIN55,212 compared to vehicle on wild- type (WT) n and knock- 
out (KO) ☐ - mice on the descent latency from a 1cm diameter bar. Significance is 
shown as “*“ for interaction effects and subsequent post- hoc test at p< 0.05, main 
effects is pictured with brackets. ........................................................................... 30	  
Figure 15: Effect of THC compared to vehicle on wild- type (WT) n and knock- out 
(KO)- ☐ mice on latency of expressing discomfort due to a painful stimulus. 
Significance is shown as “*“ for interaction effects and subsequent post- hoc test at 
p< 0.05, main effects are pictured with brackets. .................................................. 31	  
Figure 16: Effect of WIN55,212 compared to vehicle on wild- type (WT) n and knock- 
out (KO) ☐ - mice on latency of expressing discomfort due to a painful stimulus. 
Significance is shown as “*“ for interaction effects and subsequent post- hoc test at 
p< 0.05, main effects are pictured with brackets. .................................................. 32	  
Figure 17: Effect of THC n compared to vehicle (Veh) ☐ on wild- type (WT) and knock- 
out (KO)- mice on the time spend in affiliative behavior with a female partner. 
Significance is shown as “*“ for interaction effects and subsequent post- hoc test at 
p< 0.05. ................................................................................................................. 33	  
Figure 18: Effect of THC n compared to vehicle (Veh) ☐ on wild- type (WT) and knock- 
out (KO)- mice on the time spend sniffing the female. .......................................... 34	  
Figure 19: Effect of pre- treatment (Rim) n compared to pre- treatment of vehicle (Veh) 
☐ on THC- or vehicle treated in wild- type mice on the percentage of affiliative 
behavior in the first 3 minutes of the social interaction task. The control group 
(Veh/ Veh) is shown as 100%. Significance is shown as “*“ for p< 0.05. A trend 
has been taken into account at p≤ 0.06. ............................................................... 35	  
Figure 20: Effect of pre- treatment (Rim) n compared to pre- treatment of vehicle (Veh) 
☐ on THC- or vehicle treated in wild- type mice on the percentage of affiliative 
behavior in the first 3 minutes of the social interaction task. The control group 
(Veh/ Veh) is shown as 100%. .............................................................................. 36	  
Figure 21: Effect of THC n compared to vehicle (Veh) ☐ on wild- type (WT) and knock- 
out (KO)- mice on contextual freezing behavior. Significance is shown as “*“ for p< 
0.05. ...................................................................................................................... 37	  
Figure 22: Effect of THC n compared to vehicle (Veh) ☐ on wild- type and knock- out 
mice on contextual moving behavior. Significance is shown as “*“ for p< 0.05. .... 38	  
 ix 
Figure 23: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- 
type (WT) and knock- out (KO) mice on levels of ERK- phosphorylation in 
hippocampus. Main effects are pictured with brackets. ......................................... 39	  
Figure 24: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- 
type (WT) and knock- out (KO) mice on levels of AKT- phosphorylation in 
hippocampus. Main effects are pictured with brackets. ......................................... 40	  
Figure 25: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- 
type (WT) and knock- out (KO) mice on levels of S6- phosphorylation in 
hippocampus. Trend of a main effect is pictured with brackets. ............................ 40	  
Figure 26: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- 
type (WT) and knock- out (KO) mice on levels of ERK- phosphorylation in striatum. 
Significance is shown as “*“ for interaction effects and subsequent post- hoc test at 
p< 0.05, main effects are pictured with brackets. .................................................. 41	  
Figure 27: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- 
type (WT) and knock- out (KO) mice on levels of AKT- phosphorylation in striatum. 
The trend of an interaction effect and subsequent post- hoc test at p= 0.06 is 
shown as (*). ......................................................................................................... 41	  
Figure 28: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- 
type (WT) and knock- out (KO) mice on levels of S6- phosphorylation in striatum. 
Significance is shown as “*“ for interaction effects and subsequent post- hoc test at 
p< 0.05, main effects are pictured with brackets. .................................................. 42	  
Figure 29: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- 
type (WT) and knock- out (KO) mice on levels of ERK phosphorylation in cortex. 42	  
Figure 30: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- 
type (WT) and knock- out (KO) mice on AKT phosphorylation in cortex. 
Significance is shown as “*“ for interaction effects and subsequent post- hoc test at 
p< 0.05. ................................................................................................................. 43	  
Figure 31: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- 
type (WT) and knock- out (KO) mice on levels of S6- phosphorylation in cortex. 
Main effects are pictured with brackets. ................................................................ 43	  
Figure 32: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- 
type (WT) and knock- out (KO) mice on levels of ERK- phosphorylation in the 
cerebellum. Significance is shown as “*“ for interaction effects and subsequent 
post- hoc test at p< 0.05, main effects are pictured with brackets. ....................... 44	  
 x 
Figure 33: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- 
type (WT) and knock- out (KO) mice on levels of S6- phosphorylation in the 
cerebellum. ............................................................................................................ 44	  
Figure 34: mGluR5 signaling, adapted from Di Marzo (2010). The figure shows 2-AG 
synthesis via mGluR5 activation followed by CB1 stimulation. mGluR5= 
metabotropic glutamate receptor 5, DAGLalpha= diacylglycerol lipase alpha, 2-
AG= 2- Arachidonylglycerol, CB1= cannabinoid receptor 1. ................................. 47	  
Figure 35: Possible mechanism of suppressing CB1 signaling after GIRK-activation in 
Purkinje cells. ........................................................................................................ 54	  
 xi 
Abbreviations 
 
(m)RNA (messenger) Ribonucleic acid 
2- AG  2- Arachidonoylglycerol 
AEA  Anandamide 
ASD  Autism Spectrum Disorder 
BSA  Bovine serum albumin 
BW  Body weight 
CA1- 3  Cornu amonis region 1- 3 
CB1  Cannabinoid Receptor 1 
CB2  Cannabinoid Receptor 2 
CNS  Central nervous system 
COX- 2 Cyclooxygenase 2 
DAG  Diacylglycerol 
DAPI  4,6- diamidino- 2- phenylindole 
DEPC  Diethylpyrocarbonate 
DIG  Digoxygenin 
DMSO  Dimethyl sulfoxide 
DNA  Desoxyribonucleic acid 
DSM- IV Diagnostic and Statistical Manual of Mental Disorders 4th Edition 
DSM- V Diagnostic and Statistical Manual of Mental Disorders 5th Edition 
ECS  Endocannabinoid system 
FISH  Fluorescent in situ hybridization 
Fmr1- gene Fragile X mental Retardation gene 
FMRP  Fragile X Mental Retardation Protein 
FXS  Fragile X syndrome 
GIRKs  G protein coupled inwardly rectifying potassium channels 
HRP  Horseradish peroxidase 
i.p.   Intraperitoneal 
kDa  Kilodalton 
KO  Knock- out 
MAPK  Mitogen- activated protein kinase 
mGluR  Metabotropic glutamate receptor   
mGluR5 Metabotropic glutamate receptor 5 
PBS  Phosphate buffered saline 
 xii 
PFA  Paraformaldehyde 
SDS  Sodium dodecyl sulfat 
SDS- page Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SSC  Saline sodium citrate buffer 
TBS  Tris buffered saline 
TBS- T  Tris buffered saline plus Tween20 
THC  Tetrahydrocannabinol 
TNT  2,4,6- trinitrotoluene 
TRPV2 Transient receptor potential V2 
TSA  Tyramide signal amplification 
Veh  Vehicle solution 
WT  Wild- type 
 
 
 1 
1 Introduction 
 
In this chapter autism spectrum disorder, fragile X syndrome, mouse models for fragile 
X syndrome and the endocannabinoid system will be described. 
1.1 Autism Spectrum Disorder 
 
The medical term “autism” derives from the Greek word “autos” for “self” and was used 
in the 19th century to describe a pathological condition of egocentricity and social with-
drawal in schizophrenic patients (Möller, 2011). Nowadays autism is perceived as a 
mental congenital and incurable developmental disorder associated with genetic and 
environmental factors and a highly complex symptomatology. The designation “autism 
spectrum disorder” (ASD) includes different forms, symptoms and degrees of severity 
to live up to the complex manifestation of the disease. The “Diagnostic and Statistical 
Manual of Mental Disorders” (DSM)- V from 2013 incorporates several previously sep-
arated diagnoses including autistic disorder, Asperger’s disorder, childhood disintegra-
tive disorder and pervasive developmental disorder not otherwise specified (American 
Psychiatric Association, 2013). According to the DSM- V ASD is a pervasive develop-
mental disorder mainly diagnosed in children before their third year of age. 2-5 of 
10.000 children are suffering from ASD and boys are affected four times more often 
than girls (Baio, 2012). Diagnostic criteria presented by the DSM- V include a triad of 
core symptoms: 1. qualitative impairment in social interaction, 2. qualitative impairment 
in communication, and 3. restricted, repetitive and stereotype patterns of behavior, in-
terests and activities. Further diagnostic criteria with onset prior to the 3rd year of age 
are delays or abnormal functioning within at least one of the areas: social interaction, 
language use in social communication and symbolic or imaginative play, and the dis-
turbance is not better accounted for by Rett’s Disorder or Childhood Disintegrative Dis-
order (American Psychiatric Association, 2013). Besides these criteria, several sec-
ondary symptoms that are variable in occurrence and severity can be present in people 
suffering from ASD. They include cognitive impairment in about 75% of the patients 
(Tsai, 1999), which probably comes with long-term memory impairment and alteration 
in synaptic plasticity (Minshew and Goldstein, 2001; Pardo and Eberhart, 2007). In this 
regard a recent study could show that in ASD- affected humans as well as in animal 
models for ASD, some neurons build connections back to themselves in ladder-like 
patterns (Chung et al., 2013). Further symptoms include increased sensory reactivity 
(Baranek, 2002), a reduced prepulse inhibition of the acoustic startle response 
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(McAlonan et al., 2002; Perry et al., 2007; Yuhas et al., 2011), hyperactivity and sleep-
pattern alterations (Gail Williams et al., 2004; Polimeni et al., 2005), an increased anxi-
ety level (Muris et al., 1998), epileptic seizures (Tuchman and Rapin, 2002) and an 
altered stress response (Spratt et al., 2012).  
The etiopathology of ASD is mostly unknown. Neuropsychology explains the develop-
ment of ASD by a disturbed development of neuronal systems that are involved in 
forming central coherence (Frith, 1989), executive function (Ozonoff et al., 1991), theo-
ry of mind (Baron-Cohen et al., 1985) and empathy (Baron-Cohen, 2002). It suggests 
that inter- neuronal information transfer is reduced or otherwise modified due to local 
overconnectivity and long-rage underconnectivity between associated brain regions, 
i.a. frontal and parietal cortex, basal ganglia, thalamus and the limbic system including 
hippocampus and amygdala (Belmonte et al., 2004). Further the cerebellum seems to 
be particularly implicated in the anatomic variances with deficits of long- range connec-
tivity and altered coordination of cognitive functions (Courchesne, 1997; Courchesne et 
al., 2007). Neuroscience includes genetic factors with the development of ASD since 
twin studies indicate concordance rates for monozygotic twins at 70- 90% and 
corresponding values for dizygotic twins at 0-10% (Steffenburg et al., 1989; Bailey et 
al., 1995; Ronald and Hoekstra, 2011). Currently scientists proceed on the assumption 
that polygenic transmission with multiple gene loci interacting as susceptibility factors 
are responsible for the development of ASD (Belzung et al., 2005; Betancur, 2011). 
Also epigenetic modifications and pre- and perinatal exposures to environmental fac-
tors are discussed to play a role (Kolevzon et al., 2007; Miyake et al., 2012).  
Until today defined mutations, genetic syndromes and de novo copy number variation 
of genes, which account for about 10-20% of ASD cases, have been identified 
(Abrahams and Geschwind, 2008). Contributing to the strong genetic influence is the 
observation, that in families in which a sibling is affected, the relative risk for a child 
being diagnosed with ASD is increased 25- fold over the population prevalence (Jorde 
et al., 1991). Furthermore, siblings and parents of affected children are more likely than 
controls to show subtle cognitive or behavioral patterns, that are qualitatively similar to 
those observed in patients (Bolton et al., 1994; Bishop et al., 2004).  
ASD treatment includes behavioral, educational and pharmacological components that 
have been shown to have positive effects on some dysfunctional autistic behavior in 
human (Bodfish, 2004; Benvenuto et al., 2013), especially when applied in early child-
hood and as intense behavioral intervention (Howlin et al., 2009).  
Still there is little evidence for the relative effectiveness of these treatment options with 
highly individual responsiveness and a positive outcome for many behavioral and 
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pharmacological interventions in the sense that some form of treatment is favorable 
over no treatment (Leskovec et al., 2008; Seida et al., 2009). A general accepted ther-
apeutic approach to ASD as well as proof for preconditions, effectiveness and efficien-
cy in a best practice model is missing.  
1.2 Animal models for Autism Spectrum Disorder 
 
Important instruments to research and to assess psychiatric conditions in a complex 
organism instead of the human body are animal models, if information cannot be ob-
tained through human studies. In order to make animal models transferable to humans, 
requirements of validity must be met. Therefore it is favorable if the cause for the ani-
mal model’s phenotype and its development is similar to the one observed in human. 
Further treatment applied to the animal model or the affected human should reduce 
symptoms equally (McKinney and Bunney, 1969; Belzung et al., 2005).  
Concerning the origin or cause of the disease, animal models can mimic ASD only to a 
certain extend since interaction of polygenetic susceptibility factors and epigenetic 
modifications are highly complex and not entirely known. Nevertheless, there are dif-
ferent approaches to employ genetically modified mouse models to ASD research giv-
en the genetic cause of the disorder and the high homology between human and 
mouse genomes (Oddi et al., 2013). One approach consists in observing autistic be-
havior in a model and searching for the possible target gene. Here, animals with al-
tered expression of vasopressin, oxytocin and dysfunctional opioid receptors have 
been observed. They display amongst others impaired or decreased social recognition 
and modified social preferences (Engelmann and Landgraf, 1994; Wersinger et al., 
2002; Bielsky et al., 2004; Wersinger et al., 2004). Another approach consists in modi-
fying target genes and evaluating possible autistic behavior. A variant of this strategy is 
the employment of a mouse model of another, better defined human genetic disorder 
that presents some of the relevant autistic core symptoms such as Fragile X Syndrome 
(Mineur et al., 2002; Belzung et al., 2005). It represents a monogenic approach to au-
tism and must be considered as reductionist and of limited validity (Belzung et al., 
2005; Oddi et al., 2013). Still the advantage of using an intelligible monogenic mouse 
model is the ability to use a well- explored genetic modified model to identify and re-
produce pathological mechanisms possibly underlying the development of ASD as a 
predominantly genetic disease (Gould and Gottesman, 2006). Apart from genetic ap-
proaches ASD research also exposes animal models to factors that are thought to in-
crease the risk for autism in humans, such as perinatal exposure to anticonvulsants, 
thalidomide or developmental deficits in serotonin synthesis (Kahne et al., 2002; Moles 
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et al., 2004; Schneider and Przewłocki, 2005). Also neonatal lesions of brain areas that 
are assumed to be connected to abnormal behavior in autistic patients have been car-
ried out, such as lesions in the cerebellum, the amygdala or the medial prefrontal cor-
tex (Vicedomini et al., 1982; Bobée et al., 2000; Wolterink et al., 2001; Diergaarde et 
al., 2005).  
To observe similarity in the development of ASD between animal models and human 
several tests assessing relevant autistic behavior have been designed, especially con-
centrating on the core symptoms of ASD. These tests can assess early social deficits 
(Ricceri et al., 2007), deficits in social interest and social novelty (Nadler et al., 2004) 
as well as deficits in direct social interaction like affiliation, grooming, sexual and ag-
gressive behavior (Terranova et al., 1993; McFarlane et al., 2008). Further, there are 
attempts to unmask qualitative impairment of communication in mice by recording ul-
trasonic vocalization at different developmental stages and contexts (Oddi et al., 2013). 
Also restricted, repetitive and stereotype behavior can be assessed by measuring be-
havioral inflexibility, impairment in reversal learning and time spend engaging in non- 
social activities like self- grooming, digging or rearing while in social encounters (Moy 
et al., 2008; Blundell et al., 2010; Mines et al., 2010).  
Concerning the requirement of a treatment that equally reduces autistic symptoms in 
animal models as well as in humans, behavioral and educational interventions are 
mainly unexplored and obviously limited. In terms of drug treatment there are different 
approaches to employ known drugs like antidepressants, antipsychotics or ampheta-
mines. The employed treatment aims to decrease comorbidities in autistic patients but 
has poorly been tested on animal models and sometimes even exhibited an opposite 
effect (Belzung et al., 2005). The absence of an appropriate drug treatment is likely 
due to the missing evidence for a molecular drug target that can be associated with 
ASD. Still, there are some new insights into cellular and molecular mechanisms possi-
bly underlying the development of an autistic phenotype in animal models, which will 
be introduced in the chapter “biochemical mechanisms underlying the Fmr1- KO phe-
notype”. 
1.2.1 A mouse model for Fragile X Syndrome 
 
The human genetic disorder Fragile X Syndrome (FXS) presents some of the relevant 
autistic core symptoms and is a well-described disorder which is caused by expansion 
of over 230 CGG repeats in the promoter region of the fragile X mental retardation 
(Fmr1)- gene, located on the X chromosome (Pieretti et al., 1991). The triplet repeat 
triggers the methylation of a regulatory site near the Fmr1- gene, which results in epi-
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genetic silencing of the gene transcription and subsequent deficiency of the encoded 
protein (Oberlé et al., 1991), known as Fragile X Mental Retardation Protein (FMRP). 
This protein plays an important role in mRNA- transport along the dendrites and the 
control of mRNA translation in neurons, both processes that are indispensably involved 
in synaptic plasticity (Martin and Huntsman, 2012). Females with the full mutation tend 
to be less severely affected than males because generally only one of their X chromo-
somes carries the mutation and random X-inactivation results in some cells being able 
to produce FMRP. Males with the full mutation are amongst others invariably mentally 
challenged and exhibit a range of cognitive and affective impairments (Tsiouris and 
Brown, 2004). Autistic features are also common: 2% of all patients with ASD have 
FXS, whereas 25% of patients with FXS meet DSM-IV criteria for ASD before their 
third year of age (Philofsky et al., 2004; Tsiouris and Brown, 2004). Further 90% of all 
patients with FXS display abnormal behavior that is also common in patients with ASD 
such as social anxiety, gaze avoidance, sensory hypersensitivity, stereotypic move-
ments, delayed speech development, poor motor coordination and echolalia (Belmonte 
and Bourgeron, 2006; Hatton et al., 2006; Geschwind and Levitt, 2007; Abrahams and 
Geschwind, 2008; Hernandez et al., 2009). Taken together, the FXS is the leading 
monogenic cause for ASD (Boyle and Kaufmann, 2010). In 1994, scientists designed a 
mouse model to study the pathophysiological mechanisms underlying mental retarda-
tion and behavioral abnormalities in humans with FXS (The Dutch-Belgian Fragile X 
Consortium, 1994). Later this mouse line became relevant to autism research. The so 
called Fmr1- knock- out (KO) mouse is a genetically modified model that has a neomy-
cin resistance cassette replacing exon 5 of the Fmr1- gene, hence it lacks Fmr1- RNA 
and FMRP and resembles FXS. It was generated by homologous recombination of a 
targeting vector into the mouse germ line using the embryonic stem cell technology 
(Mansour et al., 1988; The Dutch-Belgian Fragile X Consortium, 1994).  
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1.2.2 Autistic behavior in the Fmr1- KO mouse 
 
The Fmr1- KO mouse line displays autistic core symptoms such as impaired social 
interaction and interest as well as signs of repetitive behavior. This has been shown in 
social interaction tasks, in which mice present deficits in social recognition, reduced 
social investigation and reduced preferences for social novelty. Further, mice exhibit 
signs of repetitive behavior being persistently engaged in self- grooming during social 
interaction (Mineur et al., 2006; Mines et al., 2010; Liu et al., 2011; Pietropaolo et al., 
2011). Mild deficits in communication in this mouse line, measured by analyzing ultra-
sonic vocalization, has been reported and is object of current research (Oddi et al., 
2013). As secondary symptoms of ASD mice show cognitive impairment and reduced 
behavioral flexibility in learning tasks such as deficiencies in object recognition and 
spatial, reversal or associative learning. They further display inappropriate aggressive 
behavior in social situations as well as signs of social anxiety (The Dutch-Belgian 
Fragile X Consortium, 1994; D’Hooge et al., 1997; Paradee et al., 1999; Van Dam et 
al., 2000; Busquets-Garcia et al., 2014; Lim et al., 2014). On the other hand, mice 
show partially no or even the opposite of the expected abnormal behavior including a 
reduced sensory reactivity, an enhanced prepulse inhibition, no tendencies to epileptic 
seizures and no signs of hyperactivity or sleep- pattern alteration (Pietropaolo et al., 
2011). Concerning treatment that equally reduces the autistic phenotype in Fmr1- KO 
mice and human suffering from ASD, a lot of research was done but no substance has 
been licensed yet and the existence of a potent molecular drug target is not sufficiently 
proven (Belzung et al., 2005). In conclusion, the Fmr1- KO mouse displays some of the 
main core and secondary symptoms of an autistic phenotype, including deficits in so-
cial interaction and repetitive behavior, cognitive impairment as well as signs of in-
creased anxiety levels. Despite its reductionist origin and its limited validity, the Fmr1- 
KO mouse is a relevant and useful tool used in the experiments of this work to eluci-
date specific neurobiological mechanisms underlying the presented autistic behavior as 
well as to explore treatment options (Bernardet and Crusio, 2006; Pietropaolo et al., 
2011; Oddi et al., 2013). 
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1.2.3 Biochemical mechanisms underlying the Fmr1- KO phenotype 
 
Alterations in different neurobiochemical mechanisms have been proposed to explain 
the Fmr1- KO phenotype. For one, there is the “mGluR theory of fragile X”: FMRP con-
trols the synthesis and cellular integration of metabotropic glutamate receptors 
(mGluR). As FMRP is missing in the Fmr1- KO mouse, phenotypical characteristics are 
explained by an over- supply of active mGluRs, leading to an excessive downstream 
protein synthesis (Bear et al., 2004). Several inhibitors of glutamate receptors were 
shown to be effective in the normalization of the Fmr1- KO phenotype (Michalon et al., 
2012; Michalon et al., 2014). Further, there are findings of altered inhibitory gamma-
aminobutyric acid (GABA)- receptor signaling and altered alpha- amino- 3- hydroxy- 5- 
methyl- 4- isoxazolepropionic-acid (AMPA)- receptor dependent synaptic plasticity. 
GABA- B receptor agonist STX209 (arbaclofen) as well as a combined treatment of 
serotonin 5HT2B- and dopamine D1- receptor agonists or 5HT2A- and D2- receptor 
antagonists improve neuronal protein synthesis, AMPA- dependent synaptic plasticity 
and associative learning in the Fmr1- KO mouse (Henderson et al., 2012; Lim et al., 
2014). Other studies could show, that intracellular signaling pathways including extra-
cellular- signal regulated kinase (ERK)-, protein kinase B (AKT)- and mammalian target 
of rapamycin (mTOR)- pathways are altered in neurons of the Fmr1- KO mouse (Weng 
et al., 2008; Gross et al., 2010; Sharma et al., 2010). More precisely the early- phase 
phosphorylation of ERK is delayed and activities of AKT- and mTOR- pathways are 
increased, also found post mortem in human brain tissue of patients with FXS (Hoeffer 
et al., 2012). It has been shown that genetic reduction and pharmacological inhibition 
of mTOR- components can partially restore the Fmr1- KO phenotype (Bhattacharya et 
al., 2012; Busquets-Garcia et al., 2013).  
The indicated biochemical mechanisms are pointing to an unbalance between synaptic 
formation and excitatory and inhibitory synaptic processes in neuronal networks what 
possibly supports the development of autistic behavior in the Fmr1- KO mouse 
(Belmonte and Bourgeron, 2006). An important modulator of excitatory and inhibitory 
synaptic processes that is also involved in synaptic formation is the endocannabinoid 
system (Kano et al., 2009). The exploration of the endocannabinoid system (ECS) in 
connection with the development and treatment of autistic behavior in the Fmr1- KO 
mouse opens some new perspectives into autism research.  
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1.3 Role of the Endocannabinoid System in the development of au-
tistic behavior in the Fmr1- KO mouse 
 
The ECS is an important neuromodulatory system that became known in 1964 by the 
discovery of Tetrahydrocannabinol (Gaoni and Mechoulam, 1971). Components of the 
ECS include neurotransmitters, so called endocannabinoids named Anandamide and 
2- Arachidonylglycerol, and their receptors, cannabinoid receptor 1 (CB1) and canna-
binoid receptor 2 (CB2). The ECS is operating in physiological processes like motor 
learning, pain sensation, appetite and body temperature regulation (Kano et al., 2009) 
as well as in neurophysiological processes like synaptogenesis, synaptic plasticity and 
neuronal interconnectivity during development (Freund et al., 2003). On a neuronal 
level, endocannabinoids are synthesized as a response to mGluR activation during 
synaptic activity in the postsynapse (Varma et al., 2001). Once released into the syn-
aptic cleft, endocannabinoids travel retrograde to the presynapse where they bind and 
activate G- protein coupled CB1- receptors, illustrated in figure 1 (Kano et al., 2009). 
Due to suppression of calcium influx, the activation of CB1, the main cannabinoid re-
ceptor in the brain, leads to direct inhibition of vesicle- mediated neurotransmitter re-
lease from the presynapse and to unexcitability of the neuron through additional potas-
sium efflux. Activation of CB1 also affects the regulation of cell functions by ERK-, 
AKT-, and mTOR- protein kinases signaling pathways, illustrated in figure 2 (André and 
Gonthier, 2010). CB1 receptors are mainly expressed at presynaptic GABAergic con-
tacts and, to a lesser extend on glutamergic and serotonergic terminals (Marsicano and 
Lutz, 1999) CB1 is highly expressed in the frontal cortex, basal ganglia, hippocampus, 
amygdala, the olfactory bulb and cerebellum, modestly in the remaining cortical struc-
tures and diencephalon and less in brain stem and spinal cord (Herkenham et al., 
1991b; Mailleux and Vanderhaeghen 1992; Tsou et al., 1998).  
It is possible that the autistic phenotype of Fmr1- KO mouse is related to an altered 
ECS. The ECS is mainly represented in brain areas that have been associated with the 
development of autistic symptoms, i.e. frontal cortex, basal ganglia, hippocampus, 
amygdala and cerebellum (Belmonte et al., 2004). The ECS is directly involved in the 
regulation of emotional behavior (Martin et al., 2002) and cannabinoid treatment is 
suggested to modulate social behavior as it can decrease time rodents spent in social 
interaction (Viveros et al., 2005). Also synaptic plasticity and the regulation of excitato-
ry and inhibitory synaptic processes depend on a steadily operating ECS, mechanisms 
that have been suggested to be altered in neurons of the Fmr1- KO mouse (Freund et 
al., 2003; Lim et al., 2014). Furthermore, the synthesis of endocannabinoids is de-
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pendent on mGluR signaling, a process that is over- activated in the Fmr1- KO mouse 
according to the “mGluR theory of fragile X” (Varma et al., 2001; Bear et al., 2004) and 
may therefore lead to an altered signaling process of the ECS. Additionally, stimulation 
of CB1 activates intracellular protein kinases including ERK-, AKT- and mTOR- path-
ways, which have been shown to be quantitatively and qualitatively altered in neurons 
of Fmr1- KO mice (Weng et al., 2008; Kano et al., 2009; Gross et al., 2010; Sharma et 
al., 2010). Whether this contributes to the development of autistic behavior in the Fmr1- 
KO mouse remains unclear. To reason that this behavior is in fact due to an altered 
ECS, the functionality of the ECS must be evaluated within the autistic behavior of the 
Fmr1- KO mouse. The following work engages in this evaluation, using pharmacologi-
cal studies with CB1- agonists to investigate the functionality of the ECS in connection 
with specific autistic behavior and the effects of cannabinoid treatment in the Fmr1- KO 
mouse. It contributes to the validity criteria for the Fmr1- KO mouse model as a model 
for autism and to therapeutic approaches concerning its autistic behavior. First it was 
evaluated whether Fmr1- KO mice responded differently to acute pharmacological CB1 
stimulation. Long-term effects of CB1 stimulation on impaired social interaction were 
evaluated as well as the influence of cannabinoid treatment on deficient associative 
learning. Besides, the influence of cannabinoid treatment on the activity of altered in-
tracellular signaling protein kinases ERK, AKT and mTOR (respectively the ribosomal 
S6- kinase, that is part of the mTOR activation) were analyzed by western blot in brain 
structures with a high density of CB1 expression. 
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Figure 1: Endocannabinoid signaling, adapted from Kano et al., (2009). The figure shows endocannabinoid 
synthesis, release and action. mGluR= metabotropic glutamate receptor, PLC= phospholipase C, araG= 
arachidonate group, DAG= diacylglycerol, DGL= diacylglycerol lipase, NAPE PLD= phospholipid diester-
ase, AEA= Anandamide, 2AG= 2- Arachidonylglycerol). 
 
Figure 1 shows a metabotropic glutamate receptor stimulated by neurotransmitter re-
lease from the inhibitory or excitatory presynapse. This leads to endocannabinoid syn-
thesis and release from postsynapse and to retrograde messaging on CB1 at the pre-
synapse. This again leads to suppression of inhibition or excitation.  
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Figure 2: CB1 signaling (André and Gonthier 2010), modified. The figure shows G-protein-mediated signal-
ing pathways of CB1. Protein kinases that are in focus of this study are highlighted in bold. 
 
Figure 2 shows G-protein-mediated signaling pathways of CB1. Protein kinases that 
are in focus of this study are highlighted in bold. These are ERK= extracellular- signal 
regulated kinase, mTOR= mammalian target of rapamycin/ respectively S6= ribo-
somal S6 kinase and AKT= protein kinase B. Other pathway components shown are 
PKA= protein kinase A, AC= adenylate cyclase, ATF-2= activating transcription factor 
2, CREB= catalytic response element binding, DAG= diacylglycerol, GPR55= G pro-
tein-coupled receptor 55, IP3= inositol triphosphate, NFAT= nuclear factor of activated 
T cells, PI3K= phosphatidylinositol 3 kinase, PIP2= phosphatidylinositol diphosphate, 
PKC= protein kinase C, PLC= phospholipase C, Raf1= rapidly accelerated fibrosar-
coma kinase 1, Rap1= Ras- proximate-1, ROCK= Rho associated protein kinase, S6= 
ribosomal protein S6- kinase, c- Fos, c-Jun, elk1, Krox24= other transcription factors. 
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1.4 Aims of this work 
 
ASD is a complex developmental psychiatric disorder. Aim of this work is to assess the 
hypothesis that an altered ECS mediates autistic behavior in a valid mouse model for 
autism. By measuring behavioral and molecular reactions to CB1 stimulation in the 
Fmr1- KO mouse, the involvement of the ECS in shaping autistic behavior can be ex-
plored as well as corresponding pharmaceutical possibilities can be elucidated. This 
leads to the following objectives: 
 
1. Evaluation of typical cannabinoid- induced effects in the Fmr1- KO mouse 
compared to WT- mice 
2. Investigation of the influenceability of autistic symptoms in the Fmr1- KO 
mouse with THC treatment 
3. Analysis of the signalling cascade of the stimulated and unstimulated ECS 
in different brain regions of the Fmr1- KO mouse compared to WT- mice 
 
2 Materials and Methods 
 
Experiments consisted of behavioral tasks and western blots to investigate if and how 
CB1 stimulation influences the Fmr1- KO mouse and its autistic behavior as well as to 
determine intraneuronal mechanisms accounting for an alteration of the ECS in this 
mouse model. In the following chapters experiments and orders of experiments will be 
separated into a behavioral and an experimental part for reasons of simplification (fig-
ure 3).  
As a preliminary point mice performed the so-called tetrad experiment to evaluate the 
basic functionality of the ECS in the Fmr1- KO mouse model. To assess typical and 
acute cannabinoid- induced effects in this experiment two different CB1- agonists, THC 
and WIN55,212 were tested exploratively. Since effects of both cannabinoids were 
comparable with a slightly greater effectivity in favour of THC all following experiments 
were carried out using THC. Subsequent to the tetrad experiment mice passed through 
a social interaction task 10 and 20 days later to assess long- term effects of THC 
treatment on deficits in social interaction, a core symptom of the autistic behavior pre-
sented by the Fmr1-KO mouse (Experiment 1). Because of a surprising and marked 
long- term effect on control WT- mice the experiment was repeated with WT- mice, 
which received a CB1- antagonist prior to cannabinoid treatment to validate the in-
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volvement of CB1 (Experiment 2). This was not done in the context of ASD but as a 
contribution to the pharmacological study of long- term side effects of THC treatment. 
Further Fmr1- KO mice were tested on acute effects of THC treatment on deficits in 
associative learning, a secondary symptom of the autistic phenotype. Since the Fmr1- 
KO mouse model exhibits deficits in associative fear memory consolidation (Paradee et 
al., 1999), mice passed trough context- dependent fear conditioning task and subse-
quent THC injection to evaluate the effects of ECS- stimulation on context dependent 
learning (Experiment 3).  
Experimental studies with western blot assessed the activity status of intraneuronal 
pathway components of the ECS in the Fmr1- KO mouse as well as its stimulatability 
with THC treatment. In brain tissue homogenates of cortex, hippocampus, striatum and 
cerebellum, regions that are high in CB1 expression (Herkenham et al., 1991b; Tsou et 
al., 1998) and partially addressed to be involved in the development of autistic behavior 
(Belmonte et al., 2004; Courchesne et al., 2007), quantities of activated protein- kinas-
es ERK, AKT and S6 were measured using western blots (Experiment 4). All experi-
mental procedures were in accordance with the European Communities Council Di-
rective of 24 November 1986 (86/609/EEC) and local French legislation.  
 
 
Figure 3: Synopsis of experiments in sequence and procedure. It shows Fmr1- KO (white) and WT (black) 
mice from the B6 background in order of experimentation. Animals of each experiment 1 to 4 were naive 
before testing. 
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2.1 Animals 
 
Adult (12±1 weeks old) male Fmr1- KO and WT littermate mice from the C57BL/6J- 
(B6)- background were used for experimentation. B6 is the most widely used inbred 
strain and the first to have its genome sequenced. Animals from this background are 
as similar as possible, easily reproduced and validly used for comparing conclusions 
(Liu and Hewett, 2015). Fmr1- KO mice used for experiment 1 and 4 (see figure 3) 
were bred in the local institute. Female mice came from C57BL/6J- Fmr1tm1Cgr/Nwu 
strains and were purchased from Neuromice.org (Northwestern University, IL 60208, 
USA; MGI ID: 1857169). Males came from the C57BL/6J.129P2-Pde6b+Tyrc-ch/AntJ 
strain, purchased from Charles River (L’Arbresle, France) and The Jackson Laboratory 
(Bar Harbor, ME 04609, USA; Stock number: 004828). By mating two heterozygous 
females with a wild- type male breeding trios were performed. After 2 weeks the sire 
was removed and the females were single caged and left alone in the cage until wean-
ing of the pups. Mice were weaned at 21 days of age and group- housed with their 
same- sex littermates (3–5/cage). On the same day, tail samples were collected for 
having the mice genotyped by PCR. Males with X- chromosomal knock- out for the 
Fmr1- gene (KO) or without (WT) were used for experiments. WT mice were employed 
as the control group. B6 mice used for experiment 2 (only WT) and experiment 3 
(Fmr1- KO and WT, see figure 3) were purchased at Janvier (Le Genest-Saint-Isle, 
France). Adult (12 weeks old) virgin females of the NMRI strain were employed in addi-
tion in the social interaction task of experiment 1. Females of the NMRI strain were 
purchased from Janvier (Le Genest-Saint-Isle, France) and employed for testing after 
one week of customization to their new surroundings. NMRI mice are commonly em-
ployed in social behavior studies because of their high sociability (D'Amato and 
Pavone, 1996; Moles and D'Amato, 2000). All animals were housed in polycarbonate 
standard cages (33×15×14 cm in size; Tecniplast, Limonest, France), provided with 
sawdust bedding (SAFE, Augy, France) and a stainless steel wired lid. Food chow 
(SAFE, Augy, France) and water were provided ad libitum. The animals were main-
tained in a temperature- (22°C) and humidity- (55%) controlled vivarium, under a 
12:12h light–dark cycle (lights on at 7 a.m.).  
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2.2 Pharmacological treatment 
 
Table 1: Pharmacological treatment of mice 
Drug Form of administra-
tion 
Dose mg/kg BW Time of administration 
before testing/ sacri-
ficing 
Vehicle prepara-
tion for drugs/ 
control treat-
ment 
i.p. 5%ethanol (vol/vol), 
5%cremophor-EL 
(vol/vol), 90%saline 
(vol/vol) 
30 or 60min 
CB1- agonist 
THC i.p. 10 30min 
WIN55,212 i.p. 3 30min 
CB1- antagonist 
SR141716 (Ri-
monabant) 
i.p. 3 60min 
 
The applied doses are known to reliably induce or prevent neurocellular responses 
(Dewey 1986; Martin 1986; Little et al., 1988; Felder et al., 1995). THC was kindly pro-
vided by THC-Pharm-GmbH, WIN55,212 by Biomol-International and SR141716 by 
Sanofi-Aventis Recherche.  
2.3 Behavioral tests 
 
All behavioral tests were carried out during the light phase of the cycle (between 10 
a.m. and 3 p.m.). Mice were excluded from testing in cases of aggressive behavior 
during the test or if accounting as statistical outliers. Test designs (see table 2 to 8) 
include treatment, genotype and number (N) of mice in each group.  
2.3.1 Experiment 1: Tetrad experiment and social interaction task 
 
Experiment 1 involved the measurement of acute cannabinoid induced effects on 
Fmr1- KO and WT mice, measured in the tetrad experiment and long- term canna-
binoid induced effects on autistic behavior in this mouse model, measured in the social 
interaction task (SIT), 10 and 20 days after cannabinoid treatment.  
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2.3.1.1 Tetrad experiment 
In the tetrad experiment mice were tested on typical acute cannabinoid-induced effects 
(figure 4). These effects include hypothermia, hypolocomotion, catalepsy and analge-
sia (Martin 1986; Howlett et al., 2002b; Varvel et al., 2005; Monory et al., 2007). A 
modified standard tetrad test protocol was used for testing (Martin, et al., 1991) and 
adopted with THC and WIN55,212.  
 
 
Figure 4: Test procedure of the tetrad experiment  
 
Hypolocomotion 
2. The distance animals moved after 
injection of drug or vehicle was measured 
individually for 15 minutes. They were put 
into an automated open field system (box 
size 32x33 cm; illumination of 0–10 lux, 
MOTION, TSE systems GmbH, Germany) 
that allows recording the horizontal 
movements of the mouse and calculate the 
cumulative distance moved. 
  
Catalepsy 
3. Afterwards mice were taken from the open 
field system and immediately transferred to 
the bar catalepsy test. In this test the 
forepaws of the mouse were placed on a 1-
cm-diameter bar affixed horizontally at 3.5 
cm from the bench surface. The descent 
latency was recorded for an observation 
period of 20 s. 
 
Analgesia  
4. Finally mice were tested on a delayed 
pain reaction to a hot plate (type 12801, 
Bachofer Laboratoriumsgeräte, Reutlingen, 
Germany). They were put on the plate before 
it was heated up to 55°C and the time until 
mice showed the first signs of discomfort 
(licking or flinching of the paws or jumping on 
the plate, here defined as escape latency) 
was recorded. A cut-off time of 60 s was set 
to prevent tissue damage. 
 
 
 
Hypothermia 
1. Basal body temperature was measured in 
all animals before and 30 minutes after the 
injection of drug or vehicle using a C-1600 
infrared thermometer with a passive sensor 
that receives and measures heat radiation 
from the animal (Linear Laboratories, 
Fremont, California).  
 
 
Measuring body temperature  
i.p. injection treatment 
Immediately  
30 minutes 
Measuring body temperature  
Immediately  
Measuring distance moved, 
observation period 15 minutes 
Immediately  
Measuring descent latency from bar,  
observation period 20 seconds 
Immediately  
Observing signs of discomfort on hot plate,  
cut- off time 60 seconds  
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2.3.1.2 Social interaction task 
In the social interaction task (SIT) mice from the tetrad experiment were tested on long- 
term effects of THC treatment for deficits in social interaction. The time frame to ana-
lyze social encounter was chosen 10 and 20 days after cannabinoid treatment accord-
ing to the half- life period of active THC metabolites. Since this period lasts up to 6 
days (Law et al., 1984; Schwartz et al., 1985; Iten, 1994), an effect was still expected 
at 10. but not anymore at 20 days after treatment used as a control. Added test proce-
dures for experiment 2 are put in brackets (figure 5). 
 
 
Figure 5: Test procedure of the social interaction tasks 
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Table 2: Number (N) of mice per genotype and treatment group, that took part in each of the three tasks of 
experiment 1, the tetrad experiment and the social interaction task (SIT) after 10 days and after 20 days 
Test design of experiment 1 
Treatment WT Fmr1- KO 
 Tetrad SIT 10 days SIT 20 days Tetrad SIT 10 days SIT 20 days 
Veh N= 8 N= 6 (8) N= 6 N= 8 N=5 (8) N=5  
THC N= 7  N=7  N= 7 N= 8 N=8 N= 8 
Number (N) of mice vary between tasks. Five mice were excluded for aggression during testing 
from groups as indicated. 
Veh N= 9 - N= 6 - 
WIN55,212 N= 9 - N= 7 - 
 
Apart from the number of mice shown in table 2 there were dropouts while measuring 
the catalepsy effect in the tetrad experiment. Six THC- treated mice (3 from WT and 3 
from Fmr1- KO) presented the so called “popcorn- effect” (Adams and Martin, 1996) 
and were therefore not taken into account for statistical analyzes. This effect describes 
THC- sedated mice leaping up due to hypersensitivity to haptic or auditory stimuli. 
There were no dropouts measuring the other three effects in the tetrad experiment.  
2.3.2 Experiment 2: Social interaction task with pre- treatment of a CB1- antago-
nist 
 
Because of a strong effect on control WT mice, the social interaction task was repeated 
with naïve, purchased B6 WT mice from Janvier to verify the involvement of the CB1 
receptor on the observed effect. Therefore mice were pre-treated with Rimonabant 
(SR141716), a CB1- antagonist, to impede THC induced deficits in social interaction by 
preventing THC- binding to CB1. Due to the novelty of the designed test protocol affilia-
tive behavior was assessed in the first 3 and again in the whole 6 minutes of the exper-
iment to find out whether differences will occur depending on half time and the amount 
of time analyzed. For test procedure see figure 4: Test procedure of the social interac-
tion tasks. Table 3 shows number of mice used for testing. 3 mice were excluded for 
aggression during testing, one for accounting as statistical outlier. 
 
Table 3: Number (N) of WT- mice per pre-treatment and treatment group that took part in the repetition of 
social interaction task 10 days after treatment. Numbers of mice that were used for statistical analyzes are 
put in brackets in case of drop outs. 
Test design of experiment 2 
Pre- treatment with Rimonabant Treatment 
 Veh THC 
No pre treatment (-) N= 9 N= 9 
Pre treatment (+) N= 10 (9) N= 9 
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2.3.3 Experiment 3: Context recognition task 
 
In the context recognition task Fmr1- KO and WT mice were tested on acute effects of 
THC treatment on deficits in associative learning. In this experiment mice learn to fear 
a new environment because of its temporal association with an aversive stimulus. Ob-
servation of freezing 24 hours after conditioning in the conditioning chamber was re-
garded as contextual fear (Kim and Jung, 2006). Additionally, mice were analyzed on 
moving (all activities except grooming) to explore further behavioral aspects in this ex-
periment. A modified test protocol was used for testing (Paradee et al., 1999) and 
adopted with THC (figure 6). Table 4 shows number of mice used for testing. One 
mouse was excluded for accounting as a statistical outlier.  
  
 
Figure 6: Test procedure of the context recognition task 
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Table 4: Number (N) of mice per genotype and treatment group that took part in context recognition task. 
Number of mice that were used for statistical analyzes is put in brackets in case of drop outs. 
 
2.4 Western blot  
 
Western blotting was chronologically independent from behavioral testing. Mice used 
for experimental testing did not undergo any behavioral tasks and received pharmaco-
logical treatment as described above. Between injections a 5- minute gap left time for 
brain preparation. Mice were singly sacrificed by cervical dislocation, the head was 
directly divided from the body and opened for brain extraction. The whole brain was 
detached from the skull and immediately dissected in hippocampus, striatum, cortex 
and cerebellum according a modified dissection protocol (Spijker, 2011). Separated 
brain tissue was transferred to fresh sample tubes, directly frozen on dry ice and stored 
at -80°C until processing. Brain homogenates were prepared as described below (table 
9) and employed for western blotting. Table 5 to 8 shows the test designs of western 
blots, based on N= 6 WT mice which were vehicle treated, N= 8 WT mice which were 
THC treated, N= 9 KO mice which were vehicle treated and N= 6 KO mice which were 
THC treated. The number of mice per genotype and treatment group differs, if mice 
were excluded from testing due to failure of the blot membrane (shown as “*”, also in 
figure 7) or sample preparation errors (failure of protein assay, shown as “**”). If during 
western blot analyzes values for optical density differed extremely from others, they 
were accounted as statistical outliers (exemplary in figure 8). 
  
Table 5: Number (N) of mice per genotype and treatment group, which were used for western blotting of 
hippocampus. In brackets number of mice used for statistical analyzes after exclusion of statistical outliers. 
Test design of experiment 4 in hippocampus 
Kinase Treatment WT Treatment KO 
 Veh THC Veh THC 
(p)ERK N= 6 (5) N= 8 (7) N= 9  N= 6 
(p)AKT N= 6 N= 8 (7) N= 9 N= 6 
(p)S6 N= 6 (5) N= 8 (6) N= 9 (7) N= 6 
 
  
Test design of experiment 3 
Treatment WT Fmr1- KO 
Veh N= 5 N= 7 (6) 
THC N= 5 N= 8 
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Table 6: Number of mice per genotype and treatment group, which were used for western blotting of stria-
tum. In brackets number of mice used for statistical analyzes after exclusion of statistical outliers. 
Test design of experiment 4 in striatum 
Kinase Treatment WT Treatment KO 
 Veh THC Veh ** THC 
(p)ERK N= 6  N= 8 (7) N= 8 (7) N= 6 (5) 
(p)AKT N= 6 (5) N= 8 (7) N= 8 N= 6  
(p)S6 N= 6 (4) N= 8 (7) N= 8 N= 6 
  
Table 7: Number of mice per genotype and treatment group, which were used for western blotting of cor-
tex. In brackets number of mice used for statistical analyzes after exclusion of statistical outliers. 
Test design of experiment 4 in cortex 
Kinase Treatment WT Treatment KO 
 Veh THC Veh THC 
(p)ERK N= 4 * N= 6 * (5) N= 6 * (5) N= 6 (5) 
(p)AKT N= 6  N= 8 (7) N= 9 N= 6 
(p)S6 N= 6 (4) N= 8 (6) N= 9 (8) N= 6  
 
Table 8: Number of mice per genotype and treatment group, which were used for western blotting of cere-
bellum. In brackets number of mice used for statistical analyzes after exclusion of statistical outliers. 
(p)AKT detection in cerebellum is not presented due to experimentation errors. 
Test design of experiment 4 in cerebellum 
Kinase Treatment WT Treatmen KO 
 Veh**  THC**  Veh**  THC 
(p)ERK N= 5 N= 7 N= 8 N= 6 (5) 
(p)S6 N= 5 N= 7 N= 8 N= 6 
 
 
Figure 7: Exemplifies errors in western blot membrane (1., *) compared to an accurate one (2.) for detec-
tion of pERK in cortex. Errors of this kind result in deficient quantification of values for optical density and 
are therefore not evaluable. 
 
 
Figure 8: Exemplifies an outlier (* 27) of the western blot results, which was excluded from statistical ana-
lyzes.  
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2.4.1 Experiment 4: Western blot 
 
Western blotting was used to visualize the activity status of mitogen- activated protein 
kinases Erk (ERK), proteinkinase B (AKT) and S6 ribosomal protein (S6) in the Fmr1- 
KO mouse with and without CB1 stimulation compared to their wild- type littermates. 
High levels of phosphorylated (p) targets were considered as activation of intraneu-
ronal endocannabinoid signaling. The phosphorylation status of the selected CB1- tar-
gets was detected by quantification of optical density values of the emitted chemilumi-
nescent signal by active phospho-specific and non phospho-specific antibodies. Values 
of phosphorylated targets were normalized to the values of unphosphorylated targets 
on the same blot. 
 
Table 9: Procedure of western blotting 
Preparation/ sam-
ple processing 
- Defrosting samples on ice  
- Supplementing 500µl sample buffer (pH 7.6), protease (Roche, 1 
pellet) and phosphatase inhibitors (NaF 2mM, against serine- 
threonine phosphatases) 
- Homogenizing with Precellys®24 homogenizer at 5000 rpm 2 
times 30 seconds plus break of 10 seconds at 4°C 
- Centrifuging 10 min. at 10.000 rpm at 4°C (Eppendorf® centrifuge 
5417 R)  
- Transfer supernatant into fresh tube 
- For protein assay: 50µl from each sample comparing to prepared 
albumin standard of 0µg/ml to 2µg/ml. 1ml bicinchoninic acid 
added as working reagent to each assay (chelating and coloring 
effects on sample proteins, induces a light absorption maximum 
at 562nm) Incubation in a water bath at 37°C for 30 min. Trans-
fer to cuvettes for protein content determination with spectro-
photometric analyzes (DU 700 Beckmann® Life Science UV/vis 
spectrophotometer) 
- Taking 300µg of protein from each sample and centrifuging for 10 
minutes at 13.000rpm at 4°C (Eppendorf® centrifuge 5415 R) 
-  Dropping supernatant, diluting pellet in 100µl laemmli sample 
buffer (removes secondary and tertiary structure of sample pro-
teins and charges them negative with sodium dodecyl sulfate 
(SDS)) 
-  Boiling samples at 95°C for 5 min 
-  Cooling down and then freezing samples at minus 20°C until be-
ing used for western blotting 
Western blotting - Preparation of Tris- glycine 10% acrylamide gels (see adden-
dum for protocol) in BioRad® Criterion midi format gel system. 
Components held clean with ethanol and distilled water 
- Transfere polymerized gel to a SDS-buffer (BioRad®)- filled 
running chamber 
- Carefully taking out spacers, washing wells with running buffer  
- Adding 10µl (equaling 30µg of protein) of each sample plus 5µl 
of prestained molecular weight standards for the first lane.  
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- Order of gel lanes for each blot, repeated until no lane left: 
 
- Running gel for about 1,5 hours at 125V. Negative charged 
SDS- covered proteins move to the cathode whereupon smaller 
proteins migrate faster and proteins are thus separated by size, 
usually measured in kilodaltons (kDa) 
- Assembling gel with ethanol activated PVDF membranes, 
Whatman- papers and sponges and submerging the assembly 
in cold transfer buffer containing Tris, glycine and ethanol 
- Transferring protein from gel to membrane for 2 hours at 
250mA at 4°C in the blotting unit filled with transfer buffer  
- After blotting membranes were saturated for 30min in 5ml Tris 
buffered saline+ 0.1%Tween20 (TBS-T)+ 5% bovine serum al-
bumin (BSA) 
Immunodetection - Proteins were immunodetected by incubating primary antibod-
ies overnight at 4°C against  
- ERK (p44/42 MAPK, diluted 1:2000 in TBS-T 5% BSA) and 
pERK (phospho-p44/MAPK Thr202/Tyr204, diluted 1:1000 in 
TBS-T 5% BSA) 
- AKT (AKT, diluted 1:1000 in TBS-T 5% BSA) and pAKT (phos-
pho-AKT Ser 473, diluted 1:2000 in TBS-T 5% BSA)  
- S6 (S6 ribosomal protein, diluted 1:1000 in TBS-T 5% BSA) 
and pS6 (phosphor-S6 ribosomal protein Ser240/244, diluted 
1:1000 in TBS-T 5% BSA). All antibodies were obtained from 
Cell Signaling Technology 
- The next morning membranes were washed 6 times for 5 
minutes in TBS-T and re-incubated for 60 minutes at room tem-
perature with a secondary horseradish peroxidase (HRP)-
conjugated antibody, diluted in 1:3000 in 5 ml TBS-T 5% BSA 
- Adding ultra-sensitive enhanced chemiluminescent agent as 
substrate for the HPR- signaling just before 
- visualization of relevant immunoreactive bands on a ChemiDoc 
XRS System (BioRad) controlled by The Quantity One software 
v4.6.3 (BioRad).  
- Relevant bands for (p)ERK were found at 44 and 42 kDa (two 
isoforms of ERK), for (p)AKT at 60 kDa and for (p)S6 at 32 kDa.  
- Immunoblots were processed with Adobe Photoshop 7.0. For 
quantitative purposes 
- Optical density values of active phospho-specific antibodies 
were normalized to the optical density of active nonphospho-
specific antibodies. Normalized values were used for statistical 
analyzes. 
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2.5 Statistical methods  
 
In experiments with two between subject factors, genotype (WT or KO) or pre- treat-
ment (Veh or Rim) and drug treatment (cannabinoid drug or vehicle) two-way ANOVA 
was used to analyze all data. Results were considered to be significant at p≤ 0.05. A 
trend has been taken into account at p≤ 0.06. If results exhibited a significant interac-
tion of the two between subject factors or were displaying a trend, Bonferroni’s post 
hoc test was used and significance was pictured accordingly in all figures as “*” for 
p<0.05, main effects are pictured with brackets. Statistical analyzes were carried out 
using GraphPad Prism Version 5.04/d, data are presented as mean ± SEM (Bénard, 
2012). If values deviated extremely from the rest of the samples, outliers were identi-
fied at arithmetic mean of all values in one group ± two times standard deviation and 
excluded.  
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3 Results 
 
This chapter shows the statistical results of behavioral and experimental tests.  
3.1 Behavioral tests 
 
The statistical results of the behavior tests include the results of experiment 1 (tetrad 
and social interaction task), experiment 2 (Social interaction task with pre- treatment of 
a CB1- antagonist) and experiment 3 (context recognition task).  
3.1.1 Experiment 1: Tetrad experiment and social interaction task 
In the tetrad experiment mice were tested on the effectiveness of cannabinoid drugs on 
the Fmr1- KO mouse model by measuring typical acute cannabinoid- induced behavior 
using two different cannabinoid drugs. These effects include hypothermia, hypoloco-
motion, catalepsy and analgesia. 
3.1.1.1 Influence of THC on Hypothermia 
Treatment had a significant effect on body temperature change {F(1,27)= 17.72; p= 
0.003}. Mice that were treated with THC exhibited a stronger decrease in body temper-
ature compared to vehicle treated mice. Genotype did not have a significant effect on 
body temperature change {F(1,27)= 0.4; p= 0.53}. Interaction (genotype vs. treatment) 
did almost have a significant effect on body temperature change {F(1,27)= 4.02; p= 
0.055}, figure 9.  
 
 
Figure 9: Effect of THC compared to vehicle on wild- type (WT) n and knock- out (KO) ☐ - mice on body 
temperature decrease. Significance is shown as “*“ for interaction effects and subsequent post- hoc test at 
p< 0.05, main effects are pictured with brackets. 
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3.1.1.2 Influence of WIN55,212 on Hypothermia 
Treatment had a significant effect on body temperature change {F(1,27)= 53.55; p< 
0.0001}. Mice that were treated with WIN55,212 exhibited a decrease in body tempera-
ture compared to vehicle treated mice. Genotype did not have a significant effect on 
body temperature change {F(1,27)= 2.34; p= 0.14}. Interaction (genotype vs. treat-
ment) did not have a significant effect on body temperature change {F(1,27)= 1.91; p= 
0.18}, figure 10.  
 
  
Figure 10: Effect of WIN55,212 compared to vehicle on wild- type (WT) n and knock- out (KO) ☐ - mice 
on body temperature decrease. Significance for main effects are pictured with brackets. 
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3.1.1.3 Influence of THC on Hypolocomotion 
Treatment had a significant effect on distance moved {F(1,27)= 114; p<0.0001}. Mice 
that were treated with THC moved less compared to vehicle treated mice. Genotype 
did not have a significant effect on distance moved {F(1,27)= 3.26; p= 0.08}. Interaction 
(genotype vs. treatment) had a significant effect on distance moved {F(1,27)= 4.97; p= 
0.03 and subsequent post-hoc test}, figure 11.  
 
 
Figure 11: Effect of THC compared to vehicle on wild- type (WT) n and knock- out (KO) ☐ - mice on the 
distance moved in an open field. Significance is shown as “*“ for interaction effects and subsequent post- 
hoc test at p< 0.05, main effects are pictured with brackets.  
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3.1.1.4 Influence of WIN55,212 on Hypolocomotion 
Treatment had a significant effect on distance moved {F(1,27)= 55.06; p< 0.0001}. 
Mice that were treated with WIN55,212 moved less compared to vehicle treated mice. 
Genotype did not have a significant effect on distance moved {F(1,27)= 2.07; p= 0.16}. 
Interaction (genotype vs. treatment) had a significant effect on distance moved 
{F(1,27)= 5.43; p= 0.03 and subsequent post-hoc test}, figure 12. 
 
  
Figure 12: Effect of WIN55,212 compared to vehicle on wild- type (WT) n and knock- out (KO) ☐ - mice 
on the distance moved in an open field. Significance is shown as “*“ for interaction effects and subsequent 
post- hoc test at p< 0.05, main effects are pictured with brackets. 
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3.1.1.5 Influence of THC on Catalepsy 
Treatment had a significant effect on catalepsy bar latency {F(1,21)= 56.24; p<0.0001}. 
Mice that were treated with THC stood longer on the catalepsy bar compared to vehicle 
treated mice. Genotype had a significant effect on catalepsy bar latency {F(1,21)= 6.82; 
p= 0.016}. WT mice stood longer on the catalepsy bar than KO mice. Interaction (geno-
type vs. treatment) had a significant effect on catalepsy bar latency {F(1,21)= 6.82; p= 
0.016 and subsequent post-hoc test}, figure 13. 
 
 
Figure 13: Effect of THC compared to vehicle on wild- type (WT) n and knock- out (KO) ☐ - mice on the 
descent latency from a 1cm diameter bar. Significance is shown as “*“ for interaction effects and subse-
quent post- hoc test at p< 0.05, main effects are pictured with brackets. 
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3.1.1.6 Influence of WIN55,212 on Catalepsy 
Treatment had a significant effect on catalepsy bar latency {F(1,27)= 58.99; p< 
0.0001}. Mice that were treated with WIN55,212 stood longer on the catalepsy bar 
compared to vehicle treated mice. Genotype had a significant effect on catalepsy bar 
latency {F(1,27)= 29.81; p< 0.0001}. WT mice stood longer on the catalepsy bar than 
KO mice. Interaction (genotype vs. treatment) had a significant effect on catalepsy bar 
latency {F(1,27)= 30.64; p< 0.0001 and subsequent post-hoc test}, figure 14.  
 
 
Figure 14: Effect of WIN55,212 compared to vehicle on wild- type (WT) n and knock- out (KO) ☐ - mice on 
the descent latency from a 1cm diameter bar. Significance is shown as “*“ for interaction effects and sub-
sequent post- hoc test at p< 0.05, main effects is pictured with brackets. 
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3.1.1.7 Influence of THC on Analgesia 
Treatment had a significant effect on latency to paw reaction {F(1,27)= 84.46; 
p<0.0001}. Mice that were treated with THC stood longer on the hot plate compared to 
vehicle treated mice. Genotype did not have a significant effect on latency to paw reac-
tion {F(1,27)= 1.39; 0.25}. Interaction (genotype vs. treatment) had a significant effect 
on latency to paw reaction {F(1,27)= 5.95; p= 0.02 and subsequent post-hoc test}, fig-
ure 15.  
 
  
Figure 15: Effect of THC compared to vehicle on wild- type (WT) n and knock- out (KO)- ☐ mice on laten-
cy of expressing discomfort due to a painful stimulus. Significance is shown as “*“ for interaction effects 
and subsequent post- hoc test at p< 0.05, main effects are pictured with brackets. 
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3.1.1.8 Influence of WIN55,212 on Analgesia 
Treatment had a significant effect on latency to paw reaction {F(1,27)= 152.70; p< 
0.0001}. Mice that were treated with WIN55,212 stood longer on the hot plate com-
pared to vehicle treated mice. Genotype had a significant effect on latency to paw reac-
tion {F(1,27)= 38.09; p< 0.0001}. WT mice stood longer on the hot plate than KO mice. 
Interaction (genotype vs. treatment) had a significant effect on latency to paw reaction 
{F(1,27)= 27.73; p< 0.0001 and subsequent post-hoc test}, figure 16.  
 
 
Figure 16: Effect of WIN55,212 compared to vehicle on wild- type (WT) n and knock- out (KO) ☐ - mice 
on latency of expressing discomfort due to a painful stimulus. Significance is shown as “*“ for interaction 
effects and subsequent post- hoc test at p< 0.05, main effects are pictured with brackets. 
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3.1.1.9 Social interaction task 10 days after THC- injection 
In the social interaction task mice from the tetrad experiment that received THC treat-
ment were tested on long- term effects of THC treatment on deficits in social interaction 
10 and 20 days after the tetrad experiment. Social interaction parameters were meas-
ured in time mice spent to nose-, body- and anogenital sniff the partner as well as allo-
grooming and traversing the partners body by crawling over and under it from one side 
to another. These parameters were observed in video recordings from the experiment 
and summarised as time mice spend in affiliative behavior. 
Treatment did not have a significant effect on affiliative behavior {F(1,22)= 0.32; p= 
0.58} Genotype did not have a significant effect on affiliative behavior {F(1,22)= 0.7; p= 
0.42}. Interaction (genotype vs. treatment) had a significant effect on affiliative behavior 
{F(1,22)= 9.87; p= 0.005 and subsequent post-hoc test}, figure 17. 
 
  
Figure 17: Effect of THC n compared to vehicle (Veh) ☐ on wild- type (WT) and knock- out (KO)- mice on 
the time spend in affiliative behavior with a female partner. Significance is shown as “*“ for interaction 
effects and subsequent post- hoc test at p< 0.05. 
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3.1.1.10 Social interaction task 20 days after THC- injection 
Treatment did not have a significant effect on affiliative behavior {F(1,22)= 0.56; p= 
0.46}. Genotype did not have a significant effect on affiliative behavior {F(1,22)= 0.02; 
p= 0.88}. Interaction (genotype vs. treatment) did not have a significant effect on affilia-
tive behavior {F(1,22)= 1,82; p= 0.19}, figure 18. 
 
 
Figure 18: Effect of THC n compared to vehicle (Veh) ☐ on wild- type (WT) and knock- out (KO)- mice on 
the time spend sniffing the female. 
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3.1.2 Experiment 2: Social interaction task with pre- treatment of a CB1- antago-
nist 
 
To reproduce the effect in WT mice from the social interaction task 10 days after THC 
treatment and to verify its dependency on CB1, purchased WT mice from the B6 back-
ground were pre- treated with either vehicle or Rimonabant and 30 minutes later addi-
tionally with THC or vehicle. Testing was done 10 days after injection, the same pa-
rameters as afore were analyzed for the first 3 and for the whole 6 minutes of social 
interaction testing. 
 
3.1.2.1 First 3 minutes of experiment 
Pre-treatment (Veh, Rim) did not have a significant effect on affiliative behavior in the 
first 3 minutes of experiment {F(1,32)= 1.418; p= 0.24}. Treatment (Veh, THC) did not 
have a significant effect on affiliative behavior in the first 3 minutes of experiment 
{F(1,32)= 0.35; p= 0.56}. Interaction (pre-treatment vs. treatment) had a significant ef-
fect on affiliative behavior in the first 3 minutes of experiment {F(1,32)= 9.70; p= 0.004 
and subsequent post- hoc test}, figure 19. 
 
 
Figure 19: Effect of pre- treatment (Rim) n compared to pre- treatment of vehicle (Veh) ☐ on THC- or vehi-
cle treated in wild- type mice on the percentage of affiliative behavior in the first 3 minutes of the social 
interaction task. The control group (Veh/ Veh) is shown as 100%. Significance is shown as “*“ for p< 0.05. 
A trend has been taken into account at p≤ 0.06. 
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3.1.2.2 6 minutes of experiment  
Pre-treatment (Veh, THC) did not have a significant effect on affiliative behavior 
{F(1,32)= 2.23; p= 0.15}. Treatment (Veh, RIM) did not have a significant effect on affil-
iative behavior {F(1,32)= 0.13; p= 0.72.}. Interaction (pre-treatment vs. treatment) did 
not have a significant effect on affiliative behavior {F(1,32)= 0.36; p= 0.55}, figure 20. 
 
 
Figure 20: Effect of pre- treatment (Rim) n compared to pre- treatment of vehicle (Veh) ☐ on THC- or vehi-
cle treated in wild- type mice on the percentage of affiliative behavior in the first 3 minutes of the social 
interaction task. The control group (Veh/ Veh) is shown as 100%. 
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3.1.3 Experiment 3: Context recognition task 
 
In the context recognition task mice were tested on acute effects of THC treatment on 
deficits in associative learning in the Fmr1- KO mouse model. In this experiment mice 
learn to fear a new environment because of its temporal association with an aversive 
stimulus (foot shock). Directly after training mice received a single THC- injection that is 
known to have an amnesic- like effects in this context. 24 hours after conditioning mice 
were replaced into the conditioning chamber, the time of freezing (no movement apart 
from breathing) was measured and regarded as contextual fear (Kim and Jung 2006). 
Additionally, mice were analyzed for moving (all activities except grooming) to explore 
further behavioral aspects in this experiment. 
 
3.1.3.1 Effect of THC on freezing 
Treatment did not have a significant effect on freezing {F(1,20)= 2.32; p= 0.14}. Geno-
type did not have a significant effect on freezing {F(1,20)= 2.02; p= 0.17}. Interaction 
(treatment vs. genotype) had a significant effect on freezing {F(1,20)= 4.74; p= 0.04 
and subsequent post- hoc test}, figure 21. 
 
 
Figure 21: Effect of THC n compared to vehicle (Veh) ☐ on wild- type (WT) and knock- out (KO)- mice on 
contextual freezing behavior. Significance is shown as “*“ for p< 0.05. 
WT KO
0
50
100
150
200
Freezing
Fr
ee
zi
ng
 (s
ec
)
THCTHC VehVeh
*
*
 
 38 
3.1.3.2 Effect of THC on moving 
Treatment did almost have a significant effect on moving {F(1,21)= 3.92; p= 0.061}. 
Genotype did not have a significant effect on moving {F(1,21)= 1.49; p= 0.24}. Interac-
tion (treatment vs. genotype) had a significant effect on moving {F(1,21)= 5.51; p= 
0.029 and subsequent post- hoc test}, figure 22. 
 
Figure 22: Effect of THC n compared to vehicle (Veh) ☐ on wild- type and knock- out mice on contextual 
moving behavior. Significance is shown as “*“ for p< 0.05. 
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3.2 Experiment 4: Western blot  
 
The effect of THC administration to Fmr1- KO an WT mice was analyzed through 
phosphorylation levels of MAP kinase Erk (ERK), proteinkinase B (AKT) and S6 ribo-
somal protein (S6) in hippocampus, striatum, cortex and cerebellum. The levels of the-
se phosphorylated (p) forms of protein are known to correlate with their activation and 
the ECS signaling status. The statistical results of these experimental tests are shown 
below. 
 
3.2.1 Effect of THC treatment on kinase- phosphorylation in hippocampus 
 
THC treatment had a significant effect on pERK levels in hippocampus {F(1,23)= 6.44; 
p= 0.02}. Genotype did not have a significant effect on pERK levels {F(1,23)= 0.017; p= 
0.9}. Interaction (genotype vs. treatment) did not have a significant effect on pERK lev-
els {F(1,23)= 1.91; p= 0.18}, figure 23. 
 
 
Figure 23: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- type (WT) and 
knock- out (KO) mice on levels of ERK- phosphorylation in hippocampus. Main effects are pictured with 
brackets.  
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THC treatment had a significant effect on pAKT levels in hippocampus {F(1,24)= 5.26; 
p= 0.03}. Genotype did not have a significant effect on pAKT levels {F(1,24)= 0.20; p= 
0.7}. Interaction (genotype vs. treatment) did not have a significant effect on pAKT lev-
els {F(1,24)= 0.86; p= 0.36}, figure 23. 
 
 
Figure 24: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- type (WT) and 
knock- out (KO) mice on levels of AKT- phosphorylation in hippocampus. Main effects are pictured with 
brackets.  
 
THC treatment almost had a significant effect on pS6 levels in hippocampus {F(1,20)= 
4.15; 0.055}. Genotype did not have a significant effect on pS6 levels {F(1,20)= 1.85; 
p= 0.19}. Interaction (genotype vs. treatment) did not have a significant effect on pS6 
levels {F(1,20)= 1.58; p= 0.22}, figure 25.  
 
 
Figure 25: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- type (WT) and 
knock- out (KO) mice on levels of S6- phosphorylation in hippocampus. Trend of a main effect is pictured 
with brackets. 
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3.2.2 Effect of THC treatment on kinase- phosphorylation in striatum 
 
In the striatum THC treatment had a significant effect on pERK levels {F(1,21)= 5.11; 
p= 0.04}. Genotype did not have a significant effect on pERK levels {F(1,21)= 1.77; p= 
0.2}. Interaction (genotype vs. treatment) had a significant effect on pERK levels 
{F(1,21)= 6.99; p= 0.02 and subsequent post-hoc test}, figure 26. 
 
 
Figure 26: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- type (WT) and 
knock- out (KO) mice on levels of ERK- phosphorylation in striatum. Significance is shown as “*“ for inter-
action effects and subsequent post- hoc test at p< 0.05, main effects are pictured with brackets. 
 
In the striatum THC treatment did not have a significant effect on pAKT levels {F(1,22)= 
0.34; p= 0.6}. Genotype did not have a significant effect on pAKT levels {F(1,22)= 1.31; 
p= 0.26}. Interaction (genotype vs. treatment) did not have a significant effect on pAKT 
levels but a trend is apparent {F(1,22)= 3.71; p= 0.06 }, figure 27. 
 
 
Figure 27: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- type (WT) and 
knock- out (KO) mice on levels of AKT- phosphorylation in striatum. The trend of an interaction effect and 
subsequent post- hoc test at p= 0.06 is shown as (*). 
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In the striatum THC treatment had a significant effect on pS6 levels {F(1,21)= 6.76; p= 
0.02}. Genotype did not have a significant effect on pS6 levels {F(1,21)= 3.26; p= 
0.09}. Interaction (genotype vs. treatment) had a significant effect on pS6 levels 
{F(1,21)= 5.15; p= 0.03 and subsequent post-hoc test}, figure 28. 
 
 
Figure 28: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- type (WT) and 
knock- out (KO) mice on levels of S6- phosphorylation in striatum. Significance is shown as “*“ for interac-
tion effects and subsequent post- hoc test at p< 0.05, main effects are pictured with brackets. 
 
3.2.3 Effect of THC treatment on kinase- phosphorylation in cortex 
 
In the cortex THC treatment did not have a significant effect on pERK levels {F(1,15)= 
0.22; p= 0.64}. Genotype did not have a significant effect on pERK levels {F(1,15)= 
0.33; p= 0.57}. Interaction (genotype vs. treatment) did not have a significant effect on 
pERK levels {F(1,15)= 1.09; p= 0.31}, figure 29. 
 
 
Figure 29: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- type (WT) and 
knock- out (KO) mice on levels of ERK phosphorylation in cortex. 
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In the cortex THC treatment did not have a significant effect on pAKT levels {F(1,24)= 
0.60; p= 0.44}. Genotype did not have a significant effect on pAKT levels {F(1,24)= 
0.49; p= 0.49}. Interaction (genotype vs. treatment) had a significant effect on pAKT 
levels {F(1,24)= 7.64, p= 0.01 and subsequent post- hoc test}, figure 30. 
 
 
Figure 30: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- type (WT) and 
knock- out (KO) mice on AKT phosphorylation in cortex. Significance is shown as “*“ for interaction effects 
and subsequent post- hoc test at p< 0.05. 
 
In the cortex THC treatment had a significant effect on pS6 levels {F(1,20)= 4.48; p= 
0.05}. Genotype did not have a significant effect on pS6 levels {F(1,20)= 2.1; p= 0.16}. 
Interaction (genotype vs. treatment) did not have a significant effect on pS6 levels 
{F(1,20)= 1.48; p= 0.24}, figure 31 
 
Figure 31: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- type (WT) and 
knock- out (KO) mice on levels of S6- phosphorylation in cortex. Main effects are pictured with brackets. 
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3.2.4 Effect of THC treatment on kinase- phosphorylation in cerebellum 
 
In the cerebellum THC treatment had a significant effect on pERK levels 
{F(1,21)=18.15; p= 0.0003}. Genotype had a significant effect on pERK levels 
{F(1,21)= 12.18; p= 0.002}. Interaction (genotype vs. treatment) had a significant effect 
on pERK levels {F(1,21)= 27.62; p <0.0001 and subsequent post- hoc test}, figure 32. 
 
 
Figure 32: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- type (WT) and 
knock- out (KO) mice on levels of ERK- phosphorylation in the cerebellum. Significance is shown as “*“ for 
interaction effects and subsequent post- hoc test at p< 0.05, main effects are pictured with brackets. 
 
In the cerebellum THC treatment did not have a significant effect on pS6 levels 
{F(1,22)= 0.37; p= 1,49}. Genotype did not have a significant effect on pS6 levels 
{F(1,22)= 2.06; p= 0.16}. Interaction (genotype vs. treatment) did not have a significant 
effect on pS6 levels {F(1,22)= 1.11; p= 0.3}, figure 33.  
 
 
Figure 33: Effect of THC treatment n compared to vehicle treatment (Veh) ☐ on wild- type (WT) and 
knock- out (KO) mice on levels of S6- phosphorylation in the cerebellum. 
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4 Discussion 
 
Aim of this study was to develop an understanding of the functionality of the endocan-
nabinoid system in the Fmr1- KO mouse model as well as to represent the influence of 
cannabinoid treatment on its autistic behavior. This was accomplished using Fmr1- KO 
mice from the B6 background and testing them for immediate and long- term effects of 
cannabinoid treatment as well as for effects of THC treatment on specific autistic be-
havior. Finally the influence of THC treatment on kinase activation in different brain 
regions of the Fmr1- KO mouse, which are connected to autism and are high in CB1 
expression was measured with western blot.  
 
4.1 Behavioral tests 
 
The discussion concerning results from behavioral tests include the results of experi-
ment 1 (tetrad and social interaction task), experiment 2 (Social interaction task with 
pre- treatment of a CB1- antagonist) and experiment 3 (context recognition task).  
4.1.1 Fmr1 KO mice display a desensitized endocannabinoid system 
 
WIN55,212 or THC treated mice showed a significant decrease in their body tempera-
tures compared to vehicle treated mice and the genotype had no significant influence 
on body temperature in either experiment (figures 9 and 10). THC treated WT and KO 
mice showed a significant decrease in body temperature compared to vehicle treated 
WT mice. This interaction effect was almost significant if mice were treated with 
WIN55,212. Body temperature loss after cannabinoid treatment could be due to pe-
ripheral cannabinoid receptors that have been shown to play a role in the regulation of 
energy homeostasis via lipogenic mechanisms (Cota et al., 2003) as well as to exhibit 
a normal responsiveness to pharmacological inhibition in Fmr1- KO mice (Pietropaolo, 
2010).  
Tested locomotion (figures 11 and 12) showed that mice move significantly less after 
THC or WIN55,212- injection compared to vehicle treated mice. Comparing WT and 
KO mice treated with THC or WIN55,212 revealed that hypolocomotion as a cannabi-
mimetic effect is significantly less distinctive in Fmr1- KO mice.  
The catalepsy part of the experiment (figures 13 and 14) revealed a significant catalep-
tic condition after THC or WIN55,212 treatment in mice. As for hypolocomotion, the 
cannabimimetic effect was significantly less distinctive in KO mice than in WT mice. 
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Measured analgesia (figures 15 and 16) exhibited a significant latency of moving the 
paws away from the hurting stimulus in THC or WIN55,212 treated mice compared to 
mice that received vehicle treatment. THC or WIN55,212 treated WT and KO mice 
mice stayed significantly longer on the hot plate than vehicle treated WT mice. Again 
the effect was less distinctive in KO mice, especially if mice were treated with 
WIN55,212.  
Taken together the first results of the tetrad experiment revealed an impaired occur-
rence of typical immediate effects of cannabinoid treatment in the Fmr1- KO mouse. 30 
minutes after cannabinoid treatment, KO mice showed significantly less signs of can-
nabinoid- induced behavior such as hypolocomotion, catalepsy and analgesia com-
pared to their wild- type littermates. These results can be interpreted as desensitization 
to cannabinoids and it strongly suggests an alteration of the functionality of the ECS in 
the Fmr1- KO mouse model. In reference to the “mGluR theory of fragile X”, a possible 
explanation for its altered functionality could be the neuronal increase of mGluR- activi-
ty that leads to an oversupply of endocannabinoids by augmenting their synthesis 
(Varma et al., 2001; Bear et al., 2004) and therefore to a general desensitization to 
cannabinoids. In fact, electrophysiological research could show that the ability of 
mGluR to mobilize endocannabinoids is heightened in the CA1 region of the hippo-
campus in Fmr1- KO animals from a B6 background (Zhang and Alger, 2010).  
Further, it was shown that one of the affected glutamate receptors in the Fmr1- KO 
mouse is the metabotropic glutamate receptor 5, mGluR5 (Maccarrone et al., 2010). 
This receptor activates a diacylglycerol lipase (DGL/ DAGL), the main responsible en-
zyme for the synthesis of the endocannabinoid 2-AG (Varma et al., 2001; Maccarrone 
et al., 2008; Kano et al., 2009), illustrated in figures 1 and 34. The absence of the Frag-
ile X Mental Retardation Protein (FMRP) results in heightened intracellular signaling of 
mGluR5 (Bear et al., 2004; Bear, 2005; Dölen et al., 2007; Michalon et al., 2012) and 
as a consequence into constant 2-AG production. Also, a local overproduction of 2- AG 
due to the loss of FMRP in hippocampal neurons cultured from Fmr1- KO mice has 
been suggested (Straiker et al., 2013).  
A permanent oversupply of endocannabinoids could lead to an altered ECS signaling 
and a modified drug effect of cannabinoid drugs because of a diminishing supply of 
CB1 receptors in the brain of the Fmr1- KO mouse as a result of decreased receptor 
synthesis or receptor mediated endocytosis as recognized mechanisms in the down-
regulation of transmembrane signal transduction (Tsao et al., 2001).  
Further, a decreased CB1 synthesis might be due to the absence of FMRP, since 
FMRP is an important factor in protein synthesis and transport as well as cell mem-
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brane assembly in neurons. Contradictory, different work found no decrease in protein 
levels of CB1 in western blots (Zhang and Alger, 2010).  
Furthermore, a defective ECS signaling could come into being by a frequent and unco-
ordinated surplus of endocannabinoids in brains of Fmr1-KO mice that results in an 
uncoordinated activation of intracellular CB1 pathway components because of an un-
coordinated CB1 stimulation. This could lead to modification of intracellular CB1- sig-
naling as well as to an insensitivity to externally applied CB1 agonists like THC or 
WIN55,212. The hypothesis of an altered intracellular pathway component activation 
status in the Fmr1- KO mouse model and its stimulatability will be discussed in chapter 
4.2. 
 
 
Figure 34: mGluR5 signaling, adapted from Di Marzo (2010). The figure shows 2-AG synthesis via 
mGluR5 activation followed by CB1 stimulation. mGluR5= metabotropic glutamate receptor 5, DAGLal-
pha= diacylglycerol lipase alpha, 2-AG= 2- Arachidonylglycerol, CB1= cannabinoid receptor 1. 
  
 
 48 
4.1.2 THC possibly restores impairment in social interaction in Fmr1- KO mice 
 
10 days after the tetrad experiment, THC or vehicle treated mice were used for social 
interaction testing. In this experiment, WT mice that had been treated with THC 10 
days prior to testing spent significantly less time sniffing an unknown female partner 
than vehicle treated WT mice (figure 17). This effect has not been described in litera-
ture yet. It shows that THC treatment decreases the interest for social interaction in 
tested WT mice and possibly indicates a long lasting anxiogenic effect of THC. This 
could be due to still active metabolites of THC since it is known that a single dose of 
THC may result in detectable active metabolites in urine for up to 12 days (Law et al., 
1984; Schwartz et al., 1985). Cannabinoid treatment has already been considered to 
possess some anxiogenic potency by other data that demonstrate conditioned anxio-
genic effects in rats 24 hours after cannabinoid treatment (Genn et al., 2004). 
However KO mice from this experiment show an inversed behavior. When treated with 
THC 10 days prior to testing, they spent more time sniffing an unknown female partner 
than mice that have been treated with vehicle. Although this effect was not significant it 
might suggest a positive effect of THC treatment on stimulating social interest in KO 
mice. This is especially noteworthy since this mouse model is amongst others charac-
terized by a reduction in social interest (Pietropaolo et al., 2011). Treated with THC, 
KO mice almost behaved like vehicle treated WT mice and spent distinctly more time 
sniffing an unknown female partner than WT mice that had been treated with THC. The 
effect of THC on KO mice suggests, that THC possibly restores the phenotype in the 
Fmr1- KO mouse. The effect vanishes 20 days after the injection (figure 18).  
In conclusion these results are in good agreement with the previous tetrad experiment 
as they also show an altered manner of functioning of the ECS in the Fmr1- KO 
mouse. Additionally, these results might exhibit a restoring character of cannabinoid 
treatment concerning the autistic core symptom of impaired social interaction. It is 
therefore also noteworthy that, by implication of the cannabinoid potency to restore a 
symptom of the autistic phenotype, an involvement of the ECS in the development of 
this phenotype is conceivable. Further it can be said that medical use of CB1- stimula-
tion could modulate social behavior. In fact there are some studies suggesting canna-
binoid treatment to help people overcome social anxiety (Rog et al., 2005; Frank et al., 
2008; Narang et al., 2008; Skrabek et al., 2008; Bergamaschi et al., 2011). Still, these 
trials must be seen critically since some were judged as possibly highly biased in a 
systematic review and meta- analyzes of cannabinoids for medical use (Whiting et al., 
2015). Further, cannabinoid treatment applied in these trials consisted mainly in the 
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use of THC plus cannabidiol (CBD) or only CBD. CBD is known for its anxiolytic, 
spasmolytic, antiemetic, anti-inflammatory and suggested antipsychotic effects 
(Mechoulam et al., 2007; Waldo Zuardi et al., 2012). Unlike THC, CBD has only a mi-
nor effect on CB1 (Pertwee, 2004), and shows a greater involvement in other neuronal 
mechanisms (Micale et al., 2013) including the activation of the vanilloid-receptor like 
1, also known as transient receptor potential V2, TRPV2 (Pertwee, 2006; Qin et al., 
2008). TRPV2 is further suggested to be associated with ASD as it mediates the re-
lease of oxytocin (Wainwright et al., 2004), a neuropeptide that has been found to have 
a restoring character on symptoms of ASD and their development in humans 
(Hammock and Young 2006; Bartz and Hollander 2008; Andari et al., 2010; Green and 
Hollander 2010). Also THC has been shown to act as an agonist on TRPV2, albeit less 
potent than CBD (Qin et al., 2008). Still, a synergy of both simulated receptors CB1 
and TRPV2, might be responsible for the presented effects of THC treatment on social 
behavior in the Fmr1- KO mouse. 
4.1.3 THC can reduce social interaction in wild- type mice 10 days after treatment 
 
To further assess and verify the involvement of CB1 in reduced social interaction in WT 
mice 10 days after THC treatment as shown in chapter 4.1.2, the social interaction task 
was repeated with naïve WT mice purchased from Janvier. The test protocol was modi-
fied to include a pre- treatment with the CB1- antagonist Rimonabant 30 minutes be-
fore THC injection to impede the effect of THC by preventing it to bind to CB1.  
The results of this experiment are shown in percentage of affiliative behavior to be able 
to compare them with the results from the previous social interaction task. The time the 
overall control group (Veh/ Veh- treatment, first bar in figures 19 and 20) engaged in 
affiliative behavior with a female partner is shown as 100%. Mice that had received 
only Rimonabant pre- treatment (Rim/ Veh) interacted not significantly less with the 
female partner compared to the control group (figure 19, first and second bar). This 
concludes that Rimonabant itself has no influence on the analyzed parameter. Mice 
that had received only THC treatment (Veh/ THC) interacted 25% less with the female 
partner than the control group (figure 19, first and third bar). This effect was not signifi-
cant but a trend is apparent. THC- treated WT mice from the previous social interaction 
task interacted around 35% less with the female partner than the control group which 
was significant (figure 17). Accordingly, the results do not reproduce the long-term ef-
fects of THC treatment in WT mice but they still indicate the tendency of THC to de-
crease social interaction 10 days after treatment. The origin of mice used here (pur-
chased at Janvier) differs from those of the experiment before (bred in the local institu-
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tion) and might play a role in these results. More importantly the test history of the mice 
could have an influence on the different results. While mice from the Rimonabant ex-
periment were naïve before testing, mice from the first social interaction task were not 
since they passed through the tetrad test battery beforehand. This can modulate be-
havior as it may decrease activity, exploratory sense, and emotionality in mice from the 
B6 background (McIlwain et al., 2001; Voikar et al., 2004) and thus influence behavior 
in subsequent experiments. Further, CB1- transmission has been shown to critically 
modulate the salience of rewarding and aversive emotional information (Tan et al., 
2014). It is therefore possible that THC might have amplified the emotional impact of 
test history and moreover, that mice influenced by THC during previous testing experi-
enced a lower salience for emotional information in following experiments, e.g. in the 
female partner mouse from the social interaction task. Mice that were treated with Ri-
monabant and THC (Rim/ THC) interacted not significantly more with the female part-
ner compared to the control group (figure 19, first and fourth bar). Mice that had re-
ceived only THC treatment (Veh/ THC) interacted 45% less with the female partner 
compared to mice that had first received Rimonabant before THC treatment (Rim/ 
THC, figure 19 third and fourth bar). This effect was significant and shows, that pre- 
treatment with Rimonabant impedes the effect of THC to decrease social interaction 10 
days after treatment and also verifies the involvement of CB1. However, this effect is 
only detectable in the first 3 minutes and not throughout the whole 6 minutes of the 
experiment (figure 20). This could indicate that neither THC, nor THC in combination 
with Rimonabant have a significant long term effect on social interaction behavior of 
the B6 mouse compared to the control group.  
4.1.4 THC possibly restores impaired associative fear memory consolidation in 
Fmr1- KO mice  
 
In the context recognition task, the influence of acute THC treatment on impaired asso-
ciative fear memory consolidation in the Fmr1- KO mouse was examined in context- 
dependent fear conditioning with subsequent THC injection. Mice received an aversive 
stimulus (foot shock) while exploring a new environment (conditioning in the condition-
ing chamber). After 5 minutes of conditioning mice were immediately injected with 
THC. 24 hours later conditioned fear was measured as the time mice spent freezing 
(fear) or moving (no fear).  
The results show that WT mice that had received THC treatment did not show a signifi-
cant difference of freezing or moving compared to the control group (figures 21 and 22, 
first and second bar). Therefore this experiment did not reproduce the amnesic- like 
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effect of THC on aversive learning and memory in WT mice that had been demonstrat-
ed before (Puighermanal et al., 2009). 
Vehicle treated KO mice freeze significantly less and move significantly more when 
returning to the conditioning chamber than the control group (WT vehicle treated), fig-
ures 21 and 22, comparing first and third bar. This confirms impaired associative learn-
ing in the Fmr1- KO mouse as reported before (Paradee et al., 1999; Lim et al., 2014). 
However KO mice, that had received a THC injection show no difference to the control 
group (figures 21 and 22, first and fourth bar). This suggests that they possibly recog-
nized the context in which they had experienced an aversive stimulus as well as vehi-
cle treated WT mice. Further, they freeze significantly longer and move significantly 
less than vehicle treated KO mice (figures 21 and 22, third and fourth bar). These re-
sults suggest that impaired associative learning can be influenced by THC treatment 
and, once again that CB1 stimulation possesses restoring potential on a symptom of 
the autistic phenotype of the Fmr1- KO mouse.  
The mechanism of impaired associative fear memory consolidation in untreated Fmr1- 
KO mice could again be connected to an oversupply of endocannabinoids and thus to 
an increased extinction of the aversive experience from the training day. In fact, CB1 
stimulation has been proposed to impact aversive memory consolidation trough selec-
tive inhibitory effects on local inhibitory networks in the amygdala and hippocampus 
and that endocannabinoids facilitate therefore the extinction of aversive memories 
(Marsicano et al., 2002; Azad et al., 2004).  
That additional CB1- stimulation with THC in Fmr1- KO mice on the other hand leads to 
the opposite effect on aversive learning and memory consolidation seems contradicto-
ry. Yet, previous studies have shown that endocannabinoids and externally applied 
cannabinoids like THC provoke different behavioral responses (Long et al., 2009). THC 
is a partial agonist for CB1 (Shen and Thayer, 1999) unlike the endocannabinoid 2- AG 
that is a full agonist. If both are present at the same time, a partial agonist can compete 
with a full agonist at the receptor binding site, suppress its binding to the receptor and 
inhibit the effects of the full agonist (Calvey and Williams, 2009).  
Combining this knowledge with the mGlur theory of FXS, which assumes an oversup-
ply of endocannabinoids, THC could act as a partial antagonist in the Fmr1- KO mouse 
and thereby readjust the overstimulated endocannabinoid system. This might explain 
the restoring character of THC treatment on autistic behavior in the Fmr1- KO mouse 
as demonstrated in the social interaction task (chapter 4.1.2) and this chapter. Howev-
er, it does not explain why KO mice exhibit less cannabimimetic effects shown in the 
tetrad experiment (chapter 4.1.1). Therefore the hypothesis of an altered intracellular 
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pathway component activation status in the Fmr1- KO mouse model and its stimulata-
bility was examined using western blots. 
 
4.2 Western blot reveals altered activity of CB1 downstream targets 
in Fmr1- KO mice 
 
In Experiment 4 the activity status and stimulatability of intraneuronal CB1 pathway 
components ERK, AKT and S6 were assessed using western blots from brain tissue 
homogenates of hippocampus, striatum, cortex and cerebellum from cannabinoid 
treated and untreated Fmr1- KO an WT mice. The selected brain regions are high in 
CB1 expression (Herkenham et al., 1991b; Tsou et al., 1998) and suggested to be in-
volved in the development of autistic behavior (Belmonte et al., 2004; Courchesne et 
al., 2007). Western blots were done to investigate the altered ECS signaling status in 
the Fmr1- KO mouse on a molecular level and to possibly determine its condition and 
responsiveness to THC treatment. Therefore activation levels of ERK, AKT and S6 
were analyzed in the selected brain areas. The change of the ratio of phosphorylated 
kinases to not phosphorylated kinases in favor of the phosphorylated kinases indicates 
activation.  
In the hippocampus THC treatment had a significant effect on ERK and AKT activation 
(figures 23 and 24) and no significant effect on S6 activation (figure 25) but a trend was 
detected (p= 0.055). No statement can be made about the effect of THC treatment on 
kinase activation in the different genotypes since the interaction (genotype vs. treat-
ment) was not significant (figures 23, 24, 25).  
In the striatum THC treatment had a significant effect on ERK and S6 activation (fig-
ures 26 and 28) and no significant effect on AKT activation (figure 27). The interaction 
(genotype vs. treatment) was significant for ERK and S6 activation, and a trend was 
detected for an interaction effect on AKT activation, respectively in THC treated WT 
mice (figures 26, 27, 28). This concludes that THC treatment increased ERK, S6 and 
possibly AKT activation in WT mice compared to vehicle treated WT mice. In KO mice 
THC treatment had no influence on kinase activation levels compared to vehicle treat-
ed KO mice. 
In cortex THC treatment had a significant effect on S6- activation (figure 31) but no 
significant effect on ERK and AKT activation (figures 29 and 30). THC treatment signif-
icantly induced AKT activation in WT mice (figure 30) compared to vehicle treated WT 
mice. Vehicle treated KO mice exhibited significantly higher levels of activated AKT 
compared to vehicle treated WT mice.  
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In cerebellum THC treatment and mouse genotype had a significant effect on ERK ac-
tivation (figure 32). THC treatment significantly induced ERK activation in KO mice (in-
teraction, figure 32) compared to vehicle treated KO and WT mice, and THC treated 
WT mice. THC treatment had no effect on S6 activation in WT and KO mice (figure 33). 
In summary these results show an inhomogeneous distribution of kinase activation 
after THC treatment in different brain regions of WT and KO mice. In cortex and stria-
tum of WT mice, THC treatment increased levels of activated kinases whereas THC 
treatment had no effect on levels of activated kinases in hippocampus and cerebellum. 
Therefore this experiment reproduced the effect of THC treatment on kinase activation 
in WT mice that had been demonstrated (Kano et al., 2009) but only in cortex and stria-
tum. The strong activation of ERK in hippocampus (Derkinderen et al., 2003) was not 
reproducible.  
The reason for a partially insufficient kinase activation after THC treatment could be the 
time frame in which the experiment was done. In behavioral experiments mice were 
tested 30 minutes after THC injection since this has been shown to be the best time to 
measure a response in the tetrad experiment (Martin et al., 1991). Accordingly the 
same time frame was applied in experiment 4. Yet, in N18TG2- cells maximal ERK 
phosphorylation has been suggested to occur already 5 minutes after CB1 stimulation 
(Dalton and Howlett, 2012). Therefore a shorter duration between THC treatment and 
western blot should be chosen to possibly allow for more valid results of kinase activa-
tion.  
There was no activation of CB1 targets after THC treatment in the cerebellum of WT 
mice. It is possible that cerebellic CB1 activation in WT mice mostly results in adenylat 
cyclase inhibition that would lead to inhibition of kinase activation (Breivogel and 
Childers 2000; Tonini et al., 2006). Another explanation for a missing activation of CB1 
targets in the cerebellum of WT mice would be the activation of GIRKs that are particu-
larly enriched in the Purkinje cell bodies of the cerebellum (Mackie et al., 1995; Tsou et 
al., 1998). Yet unknown mechanisms of GIRKs could lead to inhibition of CB1 after 
cannabinoid binding (illustrated in figure 35).  
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Figure 35: Possible mechanism of suppressing CB1 signaling after GIRK-activation in Purkinje cells. 
 
In KO mice THC treatment induced no significant activation of ERK, AKT or S6 in the 
hippocampus (figures 23, 24, 25), striatum (figures 26, 27. 28) and cortex (figures 29, 
30, 31). This is in accordance with findings from the tetrad experiment as it again sug-
gests diminished responsiveness to cannabinoid treatment in the Fmr1- KO mouse.  
As discussed in chapter 4.1.1, this might be due to a diminished supply of CB1 recep-
tors or due to an uncoordinated activation of intracellular CB1 pathway components, 
leading to modifications of downstream CB1- signaling and to insensitivity to THC. Ac-
cordingly, cannabinoid drugs that bind to desensitized CB1 receptors would not in-
crease the levels of activated kinases, similar to the demonstrated results. Further, the 
activation of AKT in the cortex of vehicle treated KO mice is significantly increased. 
This may suggest elevated kinase activation in the cortex as the regular condition in 
the Fmr1- KO mouse.  
However, THC treatment causes a significant ERK- activation in the cerebellum of KO 
mice (figure 32). Even though THC treatment had no significant effect on S6 activation 
(figure 33), levels of pERK in the cerebellum of KO mice after THC administration sug-
gest a strong activation of CB1 while there is no significant effect in WT mice in this 
brain area. It has been shown that the post-mortem cerebellum of humans suffering 
from a disease whose physiopathology is related to those of FXS exhibit overexpres-
sion of CB1, particularly in Purkinje cell bodies (Rodriguez-Cueto et al., 2013). Addi-
tionally cerebellar activation in autistic patients was shown to be abnormally high dur-
ing simple tasks (Allen et al., 2004). Taken together, a cerebellar lowered neuronal 
sensitivity threshold for cannabinoids is thinkable and might have led to the strong ki-
nase activation after THC treatment in Fmr1- KO mice. Also, Purkinje cell bodies have 
already been suggested to be responsible for suppression of activation of the analyzed 
CB1 targets in WT mice (Breivogel and Childers, 2000; Tonini et al., 2006). In the cer-
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ebellum of KO mice the observed increase of pERK could be due to alteration or ab-
sence of GIRKs. It is likely that GIRK mRNA is altered in the absence of FMRP since 
mRNA of other voltage- gated potassium channels has been shown to be a target of 
FMRP (Darnell et al., 2011). If GIRK somehow suppresses CB1-signal transduction in 
WT mice the absence or alteration of GIRKs in KO mice would accordingly lead to an 
increase of CB1 signaling. 
 
4.3 Conclusion 
 
In conclusion the Fmr1- KO mouse displays a distinctly reduced common responsive-
ness to cannabinoid drugs in the tetrad experiment (chapter 4.1.1) and in western blots 
(chapter 4.2). This is likely due to an altered signaling status of the ECS in this mouse 
model. The exploration of the basal intraneuronal activity status of the ECS with west-
ern blots (chapter 4.2) did not reveal conclusively in which way the ECS might be al-
tered in the Fmr1- KO mouse model. At the same time THC treatment influences the 
behavior of the Fmr1- KO mouse, as it may possess the potential to acutely (context 
recognition task, chapter 4.1.4) and in the long term (social interaction task, chapter 
4.1.2) restore symptoms of the autistic phenotype of the Fmr1- KO mouse model.  
Therefore this work suggests that the ECS plays a role in the development of the autis-
tic phenotype of the Fmr1- KO mouse model and that it can be influenced by THC 
treatment.  
The perspective of using cannabinoids such as THC as a therapeutic strategy to im-
prove autistic symptoms is considerable and the objective of today’s intense research 
(Busquets-Garcia, et al., 2013). Further, for the first time a single THC injection has 
been shown to notably reduce social interaction for up to 10 days in WT mice. 
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Abstract 
 
Background: 
Background of this work was the investigation of the endocannabinoid system (ECS) in 
the Fmr1 knock- out (KO) mouse. The Fmr1- KO mouse is a mouse model for fragile X 
syndrome (FXS). FXS is the leading monogenic cause for autism spectrum disorders 
(ASD) in humans. The Fmr1- KO mouse displays autistic behavior such as an impaired 
social interaction, repetitive behavior, cognitive deficits, increased anxiety and aggres-
siveness. Alterations of the ECS have been suggested to play a key role in the eti-
opathology of a variety of neuropsychiatric disorders. Until today, little has been de-
scribed about the involvement of the ECS in ASD. 
 
Interrogation: 
1. Evaluating the manifestation of typical cannabinoid- induced effects in the Fmr1- KO 
mouse 
2. Investigating the influenceability of autistic symptoms with THC treatment in the 
Fmr1- KO mouse  
3. Analyzing the signaling cascade of the stimulated and unstimulated ECS in different 
brain regions of the Fmr1- KO mouse 
 
Material and Methods: 
Experiments were carried out on adult (12±1 weeks old) male Fmr1- KO and Fmr1- 
wild- type (WT) mice from the C57BL/6J- (B6)- background. N= 15 mice received THC 
(10mg/kg bodyweight) and N= 16 received WIN55,212 (3mg/kg bodyweight). 30min 
after injection, the body temperature was measured and the distance animals moved in 
an open field during 15min was recorded (locomotion). Then, animals were placed with 
their forepaws onto a horizontally fixed bar and the time remaining in this position 
(catalepsy) was measured. Finally animals were placed on a preheated plate and the 
temperature at which a pain stimulus occurred was determined (testing analgesia). All 
4 experiments are called tetrad experiment. Afterwards changes in body temperature, 
locomotion, catalepsy and analgesia of the animals was evaluated. 
To explore long-term effects of THC after the tetrad, N= 15 animals were tested in a 
social interaction test with a female contact mouse, 10 and 20 days after THC treat-
ment. Therefore, the tested mouse and the contact mouse were placed together into a 
cage and the time mice spent in social interaction (nose, body and anogential sniffing, 
allogrooming and body contact) was manually quantified during 6min of recorded test-
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ing time. Another group of N= 19 received a premedication of rimonabant (Canna-
binoid-receptor 1 (CB1) antagonist, 3mg/kg bodyweight) 30min prior to THC treatment. 
Rimonabant prevents THC from binding to CB1 and therefore allows the assessment 
of the involvement of CB1 in mediating social behavior. 
Furthermore the suggestibility of context-dependent fear conditioning with THC treat-
ment has been tested on N= 13 mice. Animals were placed into a conditioning cham-
ber that delivered 6 short electric shocks with a 30sec pause to their paws (condition-
ing phase). Immediately afterwards mice received THC or placebo. 24h later context-
dependent fear was evaluated by quantification of the time mice spent freezing in the 
conditioning-chamber (fear) without receiving foot shocks.  
Intraneuronal signaling of the ECS was analyzed with N= 29 animals using western 
blots. Quantities of phosphorylated (“activated”) protein kinases (ERK, AKT and S6) 
from different brain homogenates (hippocampus, striatum, cortex and cerebellum) were 
therefore measured after THC or placebo injection (30 minutes prior to sacrificing). 
 
Results: 
Cannabinoids induced hypothermia, hypolocomotion, analgesia and catalepsy in WT- 
mice. These effects were significantly less detectable in Fmr1- KO mice. Effects of both 
cannabinoids, THC and WIN55,212, were comparable with a slightly greater but not 
significant efficiency of THC. THC treated WT- mice exhibited further reduced social 
interaction 10 days after treatment, an effect that was partially prevented by premedi-
cation with rimonabant. THC increased social interaction in Fmr1- KO mice comparable 
to the level of untreated WT- mice. THC had no effect on behavior of WT- mice in con-
text-dependent fear conditioning. Fmr1- KO mice showed significant less context-
dependent fear conditioning compared to WT- mice. THC facilitated the recognition of 
an anxiety-correlated context in Fmr1- KO mice comparable to untreated WT- mice. 
In western blots significant changes in the THC- induced signaling cascade were de-
tectable and depending on genotype, brain-region and analyzed protein-kinase.  
In the hippocampus there were no changes in untreated Fmr1- KO mice compared to 
WT- mice. THC had no effect on activation of protein-kinases in WT- and Fmr1- KO 
mice. 
In the striatum there were no changes in untreated Fmr1- KO mice compared to WT- 
mice. THC significantly increased activity of ERK, AKT and S6 in WT-mice and not in 
Fmr1- KO mice. 
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In the cortex of untreated Fmr1- KO mice AKT showed a significantly increased activity 
compared to WT- mice. THC significantly increased AKT activity in WT- mice without 
having an effect on KO- mice. 
In the cerebellum there were no changes in untreated Fmr1- KO mice compared to 
WT- mice. THC significantly increased ERK- activity in Fmr1- KO mice but had no ef-
fect on protein kinase activity in WT- mice. 
 
Conclusion: 
We observed physiological cannabinoid effects in WT- mice after treatment with THC 
and WIN55,212. These effects are significantly attenuated in Fmr1- KO mice. This may 
be interpreted as a desensitization of the ECS in the Fmr1- KO mouse. At the same 
time it was demonstrated that THC has the potential to improve context dependent 
memory consolidation and to increase social interaction in the Fmr1- KO mouse. In 
particular the influence of THC on impaired social interaction should be a target of fur-
ther investigations to find possible therapeutic options for this typical symptom of Au-
tism. Underlying molecular mechanisms remain unclear and the analysis of THC stimu-
lated intraneuronal signaling gave no clear indication of possible molecular alterations 
in the Fmr1- KO mouse. 
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Zusammenfassung 
 
Hintergrund:  
Ziel dieser Arbeit war die Untersuchung des Endocannabinoide Systems (ECS) in der 
Fmr1- knockout (KO) Maus. Die Fmr1- KO Maus ist ein Tiermodell für das Fragile X 
Syndrom (FXS). Das FXS ist die häufigste hereditäre Ursache für eine Autismus 
Spektrum Störung (ASD) beim Menschen. Auch in der Fmr1- KO Maus zeigen sich 
autistischer Verhaltensdefizite wie eine eingeschränkte sozialen Interaktion, repetitive 
Verhaltensweisen, kognitive Störungen, erhöhte Ängstlichkeit und Aggressivität. Ver-
änderungen des ECS wurden mit verschiedenen neuropsychiatrischen Erkrankungen 
in Verbindung gebracht. Wenig ist bisher zum ECS im Rahmen der ASD bekannt. 
 
Fragestellung: 
1. Untersuchungen zur Ausprägung typischer, Cannabinoid- induzierter Mecha-
nismen in der Fmr1- KO Maus im Vergleich zu Wildtyptieren  
2. Untersuchung der Beeinflussbarkeit autistischer Verhaltensweisen in der Fmr1- 
KO Maus durch eine Behandlung mit THC  
3. Analyse der intraneuronalen Signalkaskade des ECS in verschiedenen Gehirn-
regionen in der Fmr1- KO Maus im Vergleich zu Wildtyptieren  
 
Material und Methoden: 
Untersuchungen wurden an adulten (12±1 Wochen) männlichen Fmr1- KO und Wildtyp 
(WT)- Tieren (C57BL/6J-Hintergrund) durchgeführt. N= 15 Tiere erhielten THC 
(10mg/kg Körpergewicht) und N= 16 Tiere erhielten WIN55,212 (3mg/kg Körperge-
wicht). 30min nach Injektion wurde die Körpertemperatur gemessen und die Distanz 
aufgezeichnet, welche die Tiere innerhalb von 15min in einem offenen Feld zurückleg-
ten (Lokomotion). Dann wurden die Tiere mit ihren Vorderpfoten auf eine fixierte Stan-
ge platziert und die Zeit gemessen, die sie in dieser Position verharrten (Katalepsie). 
Zum Schluss wurden die Tiere auf eine erhitzte Platte gesetzt und die Temperatur be-
stimmt ab welcher ein Schmerzreiz auftrat (Prüfung auf Analgesie). Diese 4 Experi-
mente nennen sich Tetrade. Anschließend wurden sie hinsichtlich einer Veränderung 
von Körpertemperatur, Lokomotion, Katalepsie und Analgesie untersucht.  
Um langfristige THC- Effekte nach der Tetrade zu überprüfen, wurde 10 bzw. 20 Tage 
nach THC- Injektion in N= 15 Tieren ein sozialer Interaktionstest mit weiblichen Kon-
taktmäusen durchgeführt. Dafür wurde je eine Testmaus mit einer Kontaktmaus in ei-
nen Käfig gesetzt und deren Interaktion (Schnüffeln an Nase, Körper, anogenitaler Re-
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gion der Kontaktmaus, Allogrooming) für 6min aufgezeichnet und anschließend manu-
ell quantifiziert.  
Eine weitere Gruppe (N= 19) erhielt 30 min vor THC- oder Placeboinjektion eine Prä-
medikation mit Rimonabant (Cannabinoidrezeptor1 (CB1)-Antagonist; i.p., 3mg/kgKG). 
Rimonabant verhindert die Bindung von THC an CB1 und erlaubt so eine Untersu-
chung der Beteiligung des CB1- Rezeptors an der Vermittlung sozialer Interaktionsfä-
higkeit.  
Im Weiteren wurde die Beeinflussbarkeit kontextabhängiger Angstkonditionierung 
durch THC an N= 13 Tieren getestet. Die Mäuse kamen in eine Konditionierungskam-
mer in der 6 kurze Stromschläge im Abstand von 30 sec an die Pfoten abgesetzt wur-
den (Konditionierungsphase). Danach erhielten die Tiere THC oder Placebo. 24h spä-
ter erfolgte die Prüfung auf kontextabhängig gelernte Angst durch Aufzeichnen der 
Zeit, in der sie regungslos in der Konditionierungskammer verharrten (Angst), ohne 
Stromschläge zu erhalten.  
An N= 29 Tieren wurde die intraneuronale Signalkaskade des ECS mittels Western 
Blot- Analysen untersucht. Dafür wurde der Aktivitätsstatus anhand der Menge phos-
phorylierter (aktivierter) Proteinkinasen (ERK, AKT und S6) in Gehirnhomogenaten 
(Kortex, Hippocampus, Striatum und Zerebellum) bestimmt. Die Analyse erfolgte ohne 
und nach THC-Stimulierung (30 min vor Gehirnentnahme).  
 
Ergebnisse: 
Cannabinoide induzierten in Wildtyptieren eine Hypothermie, Hypolokomotion, Katal-
epsie und eine analgetische Wirkung. Diese Effekte waren in Fmr1- KO Mäusen signi-
fikant weniger nachweisbar. Die Effekte beider Cannabinoiden THC und WIN55,212 
waren vergleichbar wobei THC eine etwas stärkere Wirksamkeit als WIN55,212 zeigte 
(nicht signifikant). Wildtyptiere welche mit THC behandelt wurden zeigten darüber hin-
aus eine reduzierte soziale Interaktion 10 Tage nach Substanzapplikation, ein Effekt, 
der durch eine Vorbehandlung mit Rimonabant teilweise inhibiert werden konnte. In 
Fmr1- KO Mäusen erhöhte THC die soziale Interaktion auf das Niveau unbehandelter 
Wildtyptiere. Eine THC- Behandlung hatte keinen Effekt auf das Verhalten von Wildtyp-
tieren in der kontext-abhängigen Angstkonditionierung. Fmr1- KO Mäuse zeigten eine 
signifikant schlechtere Angstkonditionierung im Vergleich zu Wildtyptieren. THC-
Injektion in Fmr1- KO Mäusen erleichtere das Wiedererkennen des angstkorrelierten 
Kontextes, vergleichbar mit dem Niveau von Wildtyptieren. Auf neurobiologischer Ebe-
ne zeigten sich ebenfalls signifikante Veränderungen in der intrazellulären, durch En-
docannabinoide stimulierten Signalkaskade in Anhängigkeit vom Genotyp, der Gehirn-
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region und der spezifischen Proteinkinase. Unbehandelte Fmr1- KO Mäuse zeigten im 
Vergleich zu WT Mäusen eine unveränderte Aktivität von ERK, AKT und S6 im Hippo-
campus, Striatum und Cerebellum, während im Cortex die Aktivität von AKT in unbe-
handelten Fmr1- KO Mäusen im Vergleich zu WT Mäusen erhöht war. In WT Mäusen 
erhöhte THC im Striatum die Aktivität von ERK, AKT und S6 und im Kortex die von 
AKT. In Fmr1- KO Mäusen hatte THC keine Wirkung auf diese Regionen. THC hat 
keinen Effekt auf die Aktivierung der Proteinkinasen bei WT- und Fmr1- KO Mäusen im 
Hippocampus. THC erhöhte signifikant die Aktivität von ERK in Fmr1- KO Mäusen im 
Zerebellum, hatte aber keinen Effekt auf die Aktivität von Proteinkinasen in Wildtyptie-
ren. 
 
Schlussfolgerung: 
Wir beobachteten physiologische cannabinoide Effekte in WT Mäusen nach Gabe von 
THC und WIN55,212. Diese Effekte sind in Fmr1- KO Mäusen abgeschwächt. Dies 
kann als eine Desensibilisierung des ECS auf Cannabinoide interpretiert werden. 
Gleichzeitig konnte gezeigt werden, dass die Applikation von THC sowohl das Potenti-
al besitzt, die kontextabhängige Konsolidierung von Gedächtnisinhalten bei Fmr1- KO 
Mäusen zu verbessern sowie die soziale Interaktion zu steigern. Insbesondere die ge-
nauere Analyse des THC Einflusses auf die soziale Interaktion sollte Ziel weiterer Un-
tersuchungen sein, um eine mögliche therapeutische Option für dieses autische Symp-
tom zu finden. Die molekularen Mechanismen sind unklar und die Analyse der Aktivität 
intraneuronaler, durch THC aktivierter Signalkaskaden ergab keinen eindeutigen Hin-
weis auf mögliche molekulare Veränderungen. 
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Addendum 
 
Protocol for western blot preparation 
 
Laemmli sample buffer preparation 4X 
Product Stock Quantity Final concentration 
Tris  1M pH 6,8 2,5 ml 250 mM 
Glycerol  4 ml 40% 
SDS (pouder)  0.8g 8% 
Bromphenolblue  3 tips of a tip 2% 
MilliQ water  3,5 ml  
Betamercaptoethanol  1 ml 10% 
1mm thick separating gel preparation (1 gel) 
Acrylamide (BioRad)   30% 
Tris- HCL (BioRad) 1,5M pH 8,8 1,75 ml 373 mM 
SDS (BioRad) 10% 70 µl 0.1% 
Glycerol 66% 0.8 ml 7,5% 
MilliQ water  2,7 ml  
APS (BioRad) 40% 11,6 µl 0.066% 
Temed (BioRad)  4,7 µl  
Stacking gel preparation 
Acrylamide (BioRad) 30% 0.41 ml 5% 
Tris- HCL (BioRad) 0.5M pH 6,8 0.63 ml 128 mM 
SDS (BioRad) 10% 24,5 µl 0.1% 
Glycerol 66% 0.56 ml 15% 
MilliQ water  0.83 ml  
APS (BioRad) 40% 3,4 µl 0.055% 
Temed (BioRad)  2,5 µl  
	  
 
